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INTRODUCTION

Structure and Lytic Cycle.

Cytomegalovirus (CMV) is an enveloped

double-stranded DNA virus belonging to the family Herpesvirideae.

Other

human viruses which are classified in this family include Epstein-Barr
virus (EBV), herpes simplex types 1 and 2 (HSV-1, HSV-2) and varicellazoster (VZV).

The growth characteristics of these viruses in tissue

culture differ with respect to permissive cell type, length of replication cycle and extracellular viral titer (20).

HSV types 1 and 2 grow

in a variety of mannnalian cells with a short replication cycle resulting
in release of the virions into the extracellular fluid.
CMV is highly species-specific.

By comparison

Wild-type human CMV (HCMV) replicates

very slowly only in human fibroblasts with little or no release of virus
into the tissue culture fluid.

Repeated passage of HCMV isolates in

culture may eventually result in measurable viral titer in the extracellular fluid.

The titer, however, varies with the particular strain.

The complete virion of CMV is composed of a double-stranded linear
DNA-containing core, an icosahedral capsid and an envelope (123).

Elec-

tron micrographs, however, have demonstrated the presence of many incomplete viral particles.

In general four morphological types are pre-

sent: naked empty cores, naked "full" cores, enveloped empty cores and
enveloped "full" cores corresponding to intact virions (37, 44, 144).

An-

other characteristic form found in CMV-infected cells is the "dense
body", which appears to be excess viral structural proteins with an envelope.

The dense bodies carry CMV-specific antigens but have no detec1
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table DNA (56,110,124).
Electron microscopy has also been used to compare the replication
steps of RSV and CMV.

Both viruses enter cells by phagocytosis or

fusion with the plasma membrane.

Both rapidly traverse the cytoplasm to

the perinuclear area, but CMV nucleocapsids appear to acquire a fine
fibrillar coat in the cytoplasm and are subsequently disassembled much
more slowly than RSV nucleocapsids (4, 113).

Adsorption and penetration,

therefore occur equally rapidly in both HSV and CMV infections, but subsequent steps in viral replication are much slower for CMV than for RSV
(20, 137).
Epidemiology.

The slow rate of CMV replication and the highly

cell-associated nature of the virus have presented problems for diagnosing human infections.

CMV is an ubiquitous virus as demonstrated by

the high percentage of seropositive persons in various social groups.
Detectable antibody titers have been found in 53% of children in a day
care center (90), 12% of a group of pregnant women (103), 80% of the
general Swedish population (139) and 94% of homosexual men (28).

Most

infections are asymptomatic, but serious complications may occur following prenatal, perinatal or iatrogenically-induced exposure.

This last

group of patients includes organ transplant and transfusion recipients
(19,46,70,87,96,104).
Recently CMV has been linked with the acquired immune-deficiency
syndrome (AIDS) observed mainly among drug users, male homosexuals,·
Haitians and hemophiliacs (24,28,42,82,89,132).

Many of these patients

have detectable CMV antibody titers, and often the virus can be isolated
from clinical specimens (48,42) in some cases in the absence of a rising
antibody titer to CMV (29).

Other opportunistic infections such as

3

Pneumocystis carinii and Candida albicans are also frequently present,
thus the exact role of CMV in this new disease has not been established.
In a recent study disseminated CMV infection was found at autopsy in 14
out of 15 AIDS patients.

This suggests that CMV viremia may be in many

cases the immediate cause of death (79), although CMV is probably not
the agent which produces the initial inununodeficiency (38).
Congenital infection depending on the severity may result in a
range of symptoms from death to persistent viruria.
system (CNS) is most often affected.

The central nervous

Confirmation of congenital infec-

tion requires isolation of virus from specimens such as urine taken
during the first week of life (27,119).

The source of the virus appears

to be predominately a reactivation of maternal infection, although occasionally primary maternal disease occurs during pregnancy (121,139).
The severity of symptoms is greatest with primary maternal infection,
but factors such as gestational age at the time of infection and the
innnune response of the fetus may also contribute to the clinical outcome (10,91,92,120,121).
Perinatal infection is also usually maternal in origin, but nosocomial sources may produce disease in some cases (51,117,139).

The

maternal infection is again generally a reactivation of latent virus (61)
and is passed to the infant through the genital tract or in breast milk
(62,90,103).

In contrast to congenital infection, the CNS is not the

most frequently affected organ.

Instead perinatal disease may be de-

tected in the liver, spleen, kidneys and hematopoietic tissues.

In some

cases the children have neurologic sequelae even though they are initially asymptomatic.

Slow psychomotor development and loss of hearing
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may become apparent at a later age (139).

Again as with congenital dis-

ease the severity of perinatal CMV infection is greater in association
with primary maternal infection (121).
In adults CMV is often isolated from multiple transfusion recipients and renal, cardiac, or bone marrow transplant patients.

Viruria,

cytomegalic inclusion pneumonia and heterophile-negative mononucleosis
are the most common CMV-related diseases found in these patients (25,70,
95,139).

Whether the disease represents reactivation of latent virus or

exogenous donor infection has not been completely determined.

CMV has

been recovered from the buffy coat of donor blood (25,61); multiplytransfused patients show a higher rate of seroconversion, and the timing
of the rise in antibody titer is not characteristic of an anamnestic
response (96).

It would appear, therefore, that donor blood can be a

source for CMV transmission.

The possibility of reactivation of latent

infection cannot be ruled out, however, since allogeneic stimulation of
infected lymphocytes has been observed in mice (70,87).

In addition,

molecular analysis of CMV strains from a group of blood donors and their
recipients has demonstrated a lack of relatedness between the corresponding viral isolates (61).
Organ transplant recipients appear to be very susceptible to CMV
infection.

In the majority of cases the source of the virus is probably

a reactivation of latent host infection.

In one study of renal trans-

plant recipients all patients who developed active CMV infections had
detectable CMV antibody before receiving renal allografts (106).

The

CMV viremia was associated with graft dysfunction.
In a series of cardiac transplant patients (95) the donors were
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demonstrated to be the source of CMV when the recipients were seronegative for the virus.

These recipients had primary CMV infection from a

reactivation of latent virus in donor tissue or contaminating blood.
The recipients who were seropositive for CMV before transplantation and
who subsequently developed CMV viremia, most likely had a reactivation
of latent host virus, although reinfection from a nosocomial source has
been reported (133).
CMV infection in transplant or transfusion recipients, therefore,
often occurs in spite of measurable serum antibodies (30,46,54,95,96,
104), and the outcome may depend on the cellular immune response, which
is usually depressed in the presence of CMV (12,32,99,100,108,136).

In-

version of the T-cell helper/inducer ratio in patients following transplantation may be predictive of the risk of developing CMV infection
(111).

Active CMV infection may cause immunosuppression (32,102,108).

Therefore, efforts to determine the exact pathogenesis of CMV in transplant recipients have not produced conclusive answers.
Latency and Oncogenicity.

Since latency of CMV appears to play a

significant role in the pathogenesis of the virus for these immunocompromised patients, there have been a number of studies to determine the
site of the latent infection.

Polymorphonuclear and adherent mononu-

clear leukocytes seem to be the most likely sources of inactive virus
(25,30,31,67,68,107), although cultivation of cells from other sources
has occasionally resulted in productive viral infection (143) or detectable CMV antigens (101).

Factors which may trigger activation of the

virus include another acute infection (69), host immunosuppression (70)
or host response to allogeneic cells (87).
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In addition to its ability to produce latent infection, CMV may
abortively infect nonpermissive cells (9,37,39,101).

Abortive infection

may result in stimulation of cellular DNA and RNA synthesis (2,22,37).
Early viral antigens are expressed, but viral DNA cannot be detected
(23,75).

Similar abortive infections are characteristic of oncogenic

DNA viruses such as SV-40, polyoma and adenovirus (37).
There is evidence that CMV also is potentially oncogenic (1,2).
Albrecht and Rapp (1) infected nonpermissive hamster embryo fibroblasts
with a human CMV strain and obtained a cell line which produced tumors
in weanling hamsters.

After animal passage, however, no virus could be

rescued, although the tumor-bearing animals had antibodies to CMV antigens.

Another group of investigators (101) grew a cell line from in

vivo

CMV-infected human prostate cells to passage levels well above nor-

mal.

Again no virus could be rescued, the karyotype was diploid and no

tumors were produced in nude mice.

The cells were, however, no longer

contact-inhibited, and CMV-specific antigens were expressed.

Getler et

al. (39) reported transformation of human embryonic lung cells infected
at a low multiplicity of infection (MOI) with CMV.

Their cell line in-

duced tumors in nude mice, expressed CMV-specific membrane antigens and
underwent uncontrolled nuclear divisions in the presence of cytochalasin

B.
The outcome of CMV infection, therefore, may be influenced-by the
type and species of cell, the physiological state of the cell (19,22)
and the temporal expression of the viral genome (20,125,137,138).

Three

groups of virus-specific proteins have been described based on their
order of appearance and expression in the infected cell.

Immediate early

7

polypeptides (IEP) are produced in lytically-infected cells after treatment with protein synthesis inhibitors or in abortively-infected cells
(45,64,127).

There is a switch from IEP to early proteins (EP) within

two hours postinfection in lytically-infected cells.

Early proteins are

also expressed in the presence of viral DNA inhibitors and in latentlyinfected cells (6,44).

Late proteins (LP) require viral DNA synthesis

for expression and are, therefore, not produced in nonpermissive, abortively or latently-infected cells (6,43,83).

Such temporal control of

genome expression is typical of DNA viruses.

The regulatory proteins

involved may be responsible for the prolongation of the CMV lytic cycle
and for the determination of latency or persistence in non-lytic infections (137).
Molecular Characteristics of CMV DNA.

Molecular analysis of the

DNA of different HCMV isolates has been used to study the different types
of viral infection.

It is now known that the size of the infectious

HCMV genome is approximately 150 x 10
individual strains (19,40,126).
genome was 100 x 10

6

6

daltons with some variation among

Early studies had reported that the CMV

daltons, which is the size of RSV DNA.

These re-

ports also mentioned a less abundant class of molecules of 150 x 10
daltons (19,57,72,76).
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Stinski et al. (126) demonstrated that a low MOI

resulted in production of the majority of viral DNA molecules of the
larger size class.

Thus, the 100 x 10

6

dalton species represented de-

fective genomes, which appeared in larger numbers when the MOI was
greater than 1.
The structure of the CMV genome is similar to that of the herpes
simplex viruses in spite of the difference in size.

There is a long
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unique sequence (U ) bounded by inverted repeats (II),) and a shorter
1
unique sequence (US) also bounded by a different set of inverted repeats
(IRS) (Fig. 1).

The presence of submolar fragments in restriction endo-

nuclease digests of the viral DNA supports a model in which there are
four possible genome arrangements.

Inversion of each unique sequence

and its repeats relative to the other produces the four structures, which
are present in approximately equal amounts in infected cells (15,49,72,
141).
Although HSV 1 and 2 and CMV have structurally similar genomes
they appear to lack homology.

Renaturation kinetics by DNA-DNA hybrid-

ization has demonstrated less than 5% homology between HCMV strains and
HSV.

Cytomegalovirus also does not share homology with other herpes

viruses such as EBV (58).
Restriction endonuclease cleavage patterns and nucleic acid hybridization techniques have been used to determine strain variation of
CMV (61,115,128).

Strains of CMV from the same species show approx-

imately 80% or greater homology of the DNA genome (59,97), and restriction endonuclease site polymorphism has been used to determine the epidemiology of exogenous and endogenous infections (26,62,84).

Comparisons

of CMV strains using several restriction endonucleases have provided
strain-specific "fingerprints".

Huang et al. (62) studied a group of

women and their infants who had evidence of CMV infection within .the
first year of life.

The pattern of DNA restriction fragments of mother

and offspring were either identical or showed very little variation.
Repeat isolates from some of the same patients over a period of as long
as nine years showed stability of the viral genome responsible for the

9

Figure 1.

The structure of the genome of HCMV.

The four arrange-

ments are generated by the ability of each unique sequence and its associated repeats to invert in relationship to each other.
I~

=

long inverted repeat sequence

IRS

=

short inverted repeat sequence

UL

=

long unique sequence

us

=

short unique sequence

(.)

~Cl)
H

,0

(.)
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initial infection.

Only CMV isolates from the same or related persons

were essentially identical.
strains of CMV.

Unrelated controls carried heterogeneous

In spite of the apparent strain stability, however,

there is as yet no classification of CMV similar to that of HSV, which
can be separated into two types by both antigenic and molecular criteria
(71,123).
Several groups of investigators have mapped and cloned the genome
of the common laboratory strains of HCMV such as Davis (21), Towne (74)
and AD169 (49,130).

Specific cloned fragments of the DNA have been used

to look for homologous sequences in cellular DNA and other herpesviruses.

From these studies it has been determined that there are regions

of homology with cellular DNA, and that certain cloned fragments are
able to transform cells.
Nelson et al. (85) identified a 2.9 kilobase (kb) region of the
AD169 genome, which was capable of transforming NIH 3T3 cells.

This re-

gion is about 20 kb from the left end of the UL sequence (Fig. 2).

The

cells transfected with plasmids containing this part of the genome displayed anchorage independence and tumorigenicity in nude mice.

The

transcription of this region corresponds to an area of IEP messenger RNA,
although no translation product has been isolated.

Sequencing data in-

dicate that there is no viral protein product from this region, therefore, the mechanism of transformation is not known (86).
A second transforming region of the CMV genome has been reported
by Clanton et a1.· (14).

This region shows homology to one of the trans-

forming regions of HSV-2, when hybridization is performed under nonstringent conditions.

The cloned fragment from the Towne strain of CMV

12

Figure 2.

Restriction enzyme map of CMV AD169 genome.
From Greenaway et al. (48)
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hybridized to a unique fragment of AD169, but this was also different
from the transforming fragment described by Nelson (85).
ment was able to transform Syrian hamster embryo cells.

The Towne fragImmortal lines

were produced which grew in 2% serum and displayed anchorage independence.

There appear, therefore, to be two separate transforming re-

gions in the HCMV genome both of which show some homology to transforming regions previously found in HSV-2 (14).
Spector and Vacquier (116) described nucleotide sequences related
to the transforming gene (v-myc) of avian myelocytoma.tosis virus, which
were present in the genome of AD169.

u1

There were several regions in the

segment and the IRS, which showed homology to the 5' end of the v-_!!!Y£.

These regions, however, did not correspond to the transforming region
identified by Nelson et al. (85).

Since the v-myc sequence is homol-

ogous to cellular oncogenes (c-_!!!Y£), these authors postulate that there
may be early activation of c-myc followed by activation of another set
of genes to produce cell transformation.
To investigate further the relationship of these transforming regions with the known cellular and viral oncogenes (c-myc and v-myc),
Gelman et al. (41) showed that myc-homologous sequences were present in
subfragments of one of the Towne transforming fragments (14).

These re-

gions of homology in the HCMV genome, however, corresponded only to the
5' half of the c-myc and v-_!!!Y£ sequences.

Whether or not the virus

acquired these sequences by recombination with human DNA cannot yet be
determined.
There are sequences found in the intermediate repetitive class of
mammalian cellular DNA, which hybridize weakly to CMV Towne DNA frag-

15
ments containing the junction between the long and short segments and to
fragments carrying the termini of the long inverted repeat (93).

Similar

cell-virus DNA homology has been demonstrated for HSV 1 and 2 (93,98).
The inverted repeats of HSV 1 and 2 also show the strongest hybridization with cellular DNA (93).
Taken together these studies of the CMV genome indicate that some
homology exists between certain segments of the viral DNA and mannnalian
cellular DNA.

Some of these sequences may be responsible for cell trans-

formation, but what role they might play in lytic or latent CMV infection is still unknown.
Rapid Detection of CMV.

The potentially severe consequences of

CMV infection make rapid diagnosis desirable.

Routine virus cultures of

patient specimens for CMV of ten require two weeks or longer to produce
visible cytopathic effect (CPE) (27).

Serodiagnosis is the only cur-

rently available technique for detecting CMV infection in the absence of
a positive virus culture (35,36,50,56,131).

The two techniques which

show the most promise for rapid viral identification are: 1) detection
of early viral antigens with monoclonal antibodies, and 2) hybridization of viral nucleic acids with labelled probes.
Monoclonal antibodies specific for CMV-infected cells are available (47,73,94,135).

Strain AD169 was used to produce the antibodies,

but cross-reactivity with other strains of CMV from both laboratory and
clinical sources demonstrated the potential for universal detection of
CMV infections.

Several of the antibodies reacted with early CMV gly-

coproteins (47,73), which could allow rapid detection of the virus in
cell culture.

An antibody reacting with a late glycoprotein (47) also

16
was able to detect virus directly in clinical specimens.

These reports

indicate that it may be possible to develop monoclonal antibodies for
antigens present early in infection by all strains of HCMV.
For this project the technique of nucleic acid hybridization has
been chosen as a possible method for rapid detection of CMV.

Since there

is such a large percentage of DNA homology among CMV strains (58,142) it
should be possible to develop a probe which will hybridize to all HCMV.
In addition the low amount of homology between the genomes of CMV and
the other herpes viruses such as HSV-1, HSV-2 and EBV indicates that
hybridization could be expected to be specific for CMV.
The goal of this project has been to select a cloned fragment of
the CMV genome of strain AD169 (109) which is common to all strains of
the virus but unique to CMV.

Such a fragment could then be used as a

labelled probe for detection of CMV at an early stage of infection in
tissue culture or directly in clinical specimens.

The large size of the

viral DNA (150 x 106 daltons) precludes the cloning of the entire genome,
thus an appropriate fragment needs to be selected from among those produced by restriction endonuclease digestion of the viral DNA.
Two potential problems must be considered in the selection of a
cloned fragment.

First, in spite of the large degree of homology among

isolates of CMV, there is still significant lack of homology between particular segments of the genomes of individual strains.

La Femina et al.

(74) showed that CMV Davis and AD169 have 2000-4000 base pair deletions
relative to CMV Towne.

The deletions appear to occur at the extreme in-

ternal segments of the II),·

The rest of the genomes of CMV Towne and

Davis show a high degree of homology.

Westrate et al. (142) reported a

17
similar study comparing CMV AD169 and CMV SG.

The majority of the viral

DNA of the two strains cross-hybridized, but there were two areas which
did not.

These sequences were in the repeats and at the left end of the

U segment.

L

In selecting a fragment for a CMV cross-reactive probe,

therefore, it would be best to avoid fragments which may not contain sequences capable of hybridizing to all samples of HCMV DNA.
The second problem is that of homology between portions of the CMV
genome and mammalian cellular DNA sequences.

The segments of the CMV

DNA which are homologous to portions of the v-.!!!Y.£_ and c-.!!!Y.£_ genes (14,
41,85,116) and those which hybridize to intermediate repetitive cell DNA
sequences (93,98) could lead to an undesirable background level of hybridization of the probe in tissue culture.

Restriction endonuclease

maps are available for determining which fragments may contain sequences
that might increase the level of background hybridization (21,49,75,88).
To develop a probe for the purposes of this project CMV AD169 DNA
was isolated from extracellular virus in tissue culture fluid.

The DNA

was digested with BarnHI and fragments were inserted into pBR322.

The

plasmids were transformed into ]_. coli SF8 and screened for tetracycline
sensitivity.

Recombinant clones were analyzed for large inserts.

An

insert co-migrating with the CMV Bamlll A/B fragments was selected and
subsequently identified as the 15 kb B fragment.
was radiolabelled with

32

The recombinant plasmid

P-deoxycytidine by nick translation and assayed

for cross-reactivity with restriction endonuclease digests of EBV; HSV-1
and HSV-2 (80,114).

The specificity of the labelled probe was demon-

strated by hybridization to cells in tissue culture infected with different CMV strains from clinical sources.

Sensitivity of the radiolabelled

18
probe was determined by hybridization to dilutions of CMV AD169 DNA and
cell-free virus stocks.

Patient urine specimens submitted for CMV cul-

ture were used to demonstrate the potential clinical application of the
probe for CMV detection or identification.
A final phase of this project has been a comparison of the sensitivity of the probe labelled with
biotin.

32

P with the same probe labelled with

There are two potential advantages of a biotin-labelled probe

for clinical laboratory application: 1) elimination of the need for a
radioactive isotope and 2) stability of the probe activity.
The Enzo-Biochem conunercial nick translation kit was used to incorporate biotinylated deoxyuridine into the probe.

The detection sys-

tem is based on the strong binding of the protein avidin to biotin.
Avidin is tagged with horseradish peroxidase and addition of the enzyme
substrate produces a colored product at the site of binding to the
probe (4,8,80).
The biotin-labelled probe was hybridized to CMV AD169 DNA, stock
virus dilutions and cells infected with different CMV strains.

The re-

sults of these hybridizations were compared to the parallel results obtained under the same conditions with the radiolabelled probe.

MATERIALS AND METHODS
Virus.

CMV strain AD169 (109) was obtained from Dr. Marc Beem at

the University of Chicago.

A second sample of CMV AD169 was kindly

donated by Dr. Robert Betts at the University of Rochester.
Virus stocks were frozen and maintained at -70°c in medium containing 10% dimethylsufoxide (DMSO) and 10% fetal calf serum (FCS).
0

When needed the stock virus was rapidly thawed in a 35 C incubator and
diluted appropriately in Earles balanced salt solution (EBSS).

Samples

of CMV isolated from patient specimens received by the clinical microbiology laboratory at Loyola University Medical Center were also collected, passaged and stored.
Cells.

Rl.UI!an foreskin fibroblasts (HFS HR218 passage 19) were

'
purchased from HEM Research, Rockville,
MD for large-scale growth of the

virus.

Additional HFS (MRHF passage 22-23) were purchased from M.A.

Bioproducts, Walkersville, MD.

These cells were routinely passaged 1:2

up to a maximum passage of 29.

In some experiments human embryonic

lung (REL MRC-5) cells also from M.A. Bioproducts or WI-38 cells (Flow
Laboratories, McLean, VA) were used.
For storage cells were frozen and maintained under liquid nitrogen
in medium containing 10% DMSO and 10% FCS.

When needed the cells were

quickly thawed in a 35°c incubator, placed in 10 ml of EBSS and centrifuged at 1500 rpm in a Sorvall H4000 rotor at 4°c for 15 min.

The su-

pernatant was discarded and the cell pellet was resuspended in 5 ml of
growth medium (see below).

The suspension was then plated in the appro-

priate number of flasks or plates for a 1:2 split.
19
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Confluent monolayers were detached with filtered (0.22 µm Millipore) 0.25% trypsin.

Generally incubation at 35°c for 10 min was suffi-

cient for the trypsin to remove the cells; however, monolayers which had
been under maintenance medium (see below) at confluency for several days
required longer incubation times.

Detached cells, diluted 1:4 in trypan

blue, were counted with a hemocytometer.
Tissue Culture Media.

Cells were grown in Eagle's minimum essen-

tial medium (MEM) supplemented with 10% FCS, 7.5% NaHC0 , (to adjust pH
3
to 7.2), L-glutamine (1 mM), HEPES buffer (20 mM), gentamicin (50 µg/ml)
and _amphotericin B (2.5 µg/ml).

This is referred to as growth medium.

Maintenance medium was Eagle's MEM with the same supplements except only
1% FCS and no HEPES.

Earles balanced salt solution was used for washing

cell monolayers and for making serial dilutions as virus.

The overlay

for plaque assays consisted of equal parts of 0.6% agarose and double
strength maintenance medium (140).
Bacteriological Media.

L broth for growth of

!·

coli consisted of

tryptone (lOg), yeast extract (5g) and NaCl (5g) in a total volume of
1 liter.

The pH was adjusted to 7.1-7.4 with NaOH (80).

For large-scale isolation of plasmid DNA the bacteria were grown
in A.B. minimal medium consisting of K HPo (3g/l), NH Cl (lg/l),
4
4
2
Mgso .7H 0 (0.3 g/l), KCl (0.15 g/l), CaC1 .2H o
4
2
2
2

(0.0~

g/l), FeS04.7H 0
2

(2.5 mg/l), glucose (5·g/l), Casamino acids (0.5%), L-tryptophan
(25 µg/ml) and thiamine (5 µg/l) (11).
For isolation and maintenance of recombinant clones nutrient agar
plates (1.5% agar, 0.8% BBL or Difeo nutrient broth base) were used.
medium was supplemented with 100 µg/ml ampicillin or 10 µg/ml tetracycline.

The
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Reagents and Chemicals.

The following is a list of sources for

the conunonly used reagents and chemicals: FCS and amphotericin B (Fungizone) from Gibco, Grand Island, NY; EBSS, Eagle's MEM, L-glutamine,
NaHC0 , HEPES buffer and trypsin from Flow Laboratories, McLean, VA;
3
3H-t h ynu.·d·ine an d 32P- d eoxycyti·d·ine f rom New Eng 1an d Nuc 1 ear; gentamicin
(Garamycin) from M.A. Bioproducts; CsCl from Harshaw Chemical, Solon, OH;
Pronase B from Calbiochem-Behring, LaJolla, CA; Sarkosyl, sodium dodecyl
sulfate (SDS), Trizma base, disodium EDTA, bovine serum albumin (BSA),
dithiothreitol (DTT), calf thymus DNA, lysozyme and RNase A from Sigma;
restriction endonucleases BamHI, HindIII, Pstl, EcoRI and _!!g!II from
BRL, Gaithersburg, MD; boric acid, sodium citrate, sodium chloride, formamide from Mallinkrodt, St. Louis, MO; polyvinylpyrollidone (PVP),
ficoll 400, dextran sulfate and Sephadex G-50 from Pharmacia, Uppsala,
Sweden.
Plaque Assay.

The method of Wentworth and French (140) was mod-

ified for titering and plaque purifying the virus.

HFS cells were prop-

agated in growth medium in 24-well (diameter 16 mm) tissue culture
plates (Falcon 3047) until just subconfluent (at least 2-3 days) (18).
Virus dilutions from 10-l to 10- 6 were made in EBSS.

The growth medium

was removed from each well and replaced with 0.1 ml of viral inoculum.
Final viral dilutions were 100

sorb for 2 h at 35 C.

2

to 10- 7 •

The virus was allowed to ad-

The excess liquid was removed at the end of the

adsorption period and replaced with an overlay of equal parts 0.6%
agarose and double strength maintenance medium.

Seven days later a

second overlay was poured on top of the first.

Plates could then be

held for as long as 4-6 weeks without drying out.
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Plaques were counted in wells containing no more than 10-15 wellisolated plaques.

The titer in plaque-forming units (pfu) was calcu-

lated according to the dilution.

Wells containing no more than three

well-isolated plaques were selected for plaque purification.

A capil-

lary pipette was used to withdraw medium overlying well-developed
plaques.

This inoculum was then placed on HFS cell monolayers in 25 cm

2

flasks (Corning) for further culture.
Passage of Stock Virus.
days until CPE reached 80-90%.
a 10-

5

Maintenance medium was changed every 5-7
From 3-4 days after 100% CPE was evident

dilution of the extracellular fluid was made in EBSS.

A 0.1 ml

sample of the dilution was used to inoculate monolayers in 25 cm
sue culture flasks.

2

tis-

The MO! usually was low enough to maintain high-

titer virus (126).
Electron Microscopy.

Electron microscopy was performed by Dr.

Raoul Fresco, at the Loyola University Medical Center, on a preparation
of cells infected with 2 different samples of strain AD169.

The first

was a three-times plaque purified sample from the strain obtained from
Dr. Marc Beem.

The other was a one-time plaque purified sample of the

strain supplied by Dr. Robert Betts.
Large-Scale Growth of Plaque-Purified Stock Virus.

In earlier ex-

2
periments 24 tissue culture flasks (150 cm ) of HFS cell monolayers at
passage 25-27 were inoculated with 1 ml each of a 1:1,000 dilution of
virus stock supernatant.

The MO! was between 0.01 and 0.001.

The virus

was allowed to adsorb for 2 h and then 35 ml of maintenance medium was
.
3
placed in each flask. After 7-8 days each flask was labelled with Hthymidine (3 µCi/ml).

Extracellular virus was harvested at 13-15 days

23
post-infection, which was 3-4 days· after 100% CPE was reached in all
flasks.
In later experiments to increase the yield of virus, the cells
2
were initially propagated in tissue culture flasks (150 cm), and then

2
split to 10 roller bottles (850 cm).

Each roller bottle was inoculated

at subconfluency with 5 ml of a plaque-purified virus stock dilution.
The MOI was between 0.1 and 0.01.

Each roller bottle contained 125 ml

of maintenance medium, which was changed at 7 days.

The supernatant

fluid was harvested 3 days after 100% CPE was observed.
Purification of Virus From Supernatant Fluid.

Several changes in

this procedure were made from experiment to experiment to increase the
yield of DNA.

In earlier experiments the clarified supernatant fluid

was centrifuged in a Beckman Ti 45 rotor at 25,000 rpm for 1 h through a
20 ml cushion of 20% (w/v) D-sorbitol in 0.05 M Tris-hydrochloride (TrisHCl), pH 7.2, containing 0.001 M MgC1
126).

2

and 100 µg bacitracin per ml (124,

The pellets were resuspended by vortexing in a total of 1 ml Tris-

buffered saline (TBS 0.05 M Tris-HCl pH 7.2, 0.15 M NaCl) and combined.
An additional 1 ml of TBS was used to sequentially rinse out the tubes.
This was added to the combined pellet suspension.

This suspension was

layered onto a discontinuous sorbitol gradient (75%/48%/20% w/v).

The

0

gradient was centrifuged at 26,500 rpm at 20 C for 60 min in a Beckman
SW 28 rotor (130).

The visible band at the interface of 75%/48% sorbi-

tol was collected by side puncture.

This material was diluted with TBS

to 38 ml total volume and repelleted at 26,500 rpm at 20°c for 3 h in
the SW 28 rotor.
In later experiments 5% polyethylene glycol (PEG) 6000 (34,52) was
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added to the supernatant fluid to precipitate the virus.

Once the PEG

0

was dissolved the fluid was held at 4 C for 4 h and then centrifuged at
7,000 rpm for 30 min at 4°c in a Beckman JA-14 rotor.

The supernatant

fluid was poured off and the viral pellet was resuspended in TBS.

The

virus suspension was placed on a discontinuous sorbitol gradient and purified as described above.
The difficulty in resuspending PEG-precipitated virus prompted a
further modification of the pelleting procedure (65,75).

The clarified

supernatant fluid was centrifuged for 90 min at 12,000 rpm in a Sorvall
GSA rotor.

The supernatant fluid was poured off and the remaining viral

pellets were drained and resuspended in a total volume of 2 ml of buffer
(0.4 M NaCl, 5 mM Tris-HCl pH 8.0, 100 mM EDTA).

An additional 1 ml of

buffer was used to wash the centrifuge bottles to collect any residual
virus.
Extraction of Viral DNA.

In earlier experiments the final viral

pellet was resuspended in 2 ml of buffer (O.l M NaCl, 0.01 M Tris-HCl,
0.01 M EDTA pH 8.0) (130).

SDS was added to a final concentration of 1%

followed by RNase A (50 µg/ml) and pronase (1 mg/ml).

This solution was

incubated for 1 h at 37°C then extracted twice with 2 volumes phenolchlorofornrisoamyl alcohol (50:48:2) and once with 2 volumes of chlorofornrisoamyl alcohol (24:1).
The treated lysate was placed in CsCl at a density of 1.72

~/ml

and centrifuged at 35,000 rpm at 20°c for 48 h in a Beckman type 50 rotor.
The resulting gradient was fractionated; counts per minute (cpm) and refractive index for each fraction were determined.

Fractions showing peak

radioactivity and corresponding to the density of CMV DNA (1.716 g/ml)
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were pooled and dialyzed overnight with three changes of buffer (5 mM
Tris-HCl, 1 mM EDTA pH 8.0).
In later experiments a modification of the method of La Femina and
Hayward (75) was used.

RNase A (20 µg/ml) was added to the virus sus-

pension, which was then incubated at 37°c for 15 min.

Sarkosyl (2%) and

SDS (0.5%) were added, and the lysate was incubated at 37°c for 60 min.
0

Pronase (1 mg/ml) was added and incubation at 37 C was continued for an
additional 2 h.

After extraction with phenol followed by chloroform/

isomyl alcohol (98:2), the aqueous layer was dialyzed as follows: 1 h
against 2 L 10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0, 300 mM NaCl; overnight against 2 L 10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0; 1 h in another
2 L of the same buffer.
In addition to the extractiop of DNA from extracellular virions,
the remaining adherent cells were trypsinized, washed and pelleted.

The

cells were resuspended in a small volume of growth medium with 10% DMSO
and frozen at -70°c for future extraction of intracellular virion DNA.
Culture for Infectivity During Purification of Virus.

Aliquots

(O.l ml) from the original pellets, sorbitol gradient and repelleted
virions were cultured to determine the amount of viral infectivity remaining at each step.

A plaque assay was perfonned on each aliquot ac-

cording to the procedure outlined above (140).

Titers expressed as pfu

were determined after 21 days.
Concentration of DNA.

DNA samples were precipitated with 1/10

volume 3 M potassium acetate plus 2 volumes of 95% ethanol.

The samples

were then placed on dry ice for 20 min and centrifuged in a Fisher model

235 microfuge for 10 min.

The supernatant was poured off and the DNA
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precipitates were resuspended in a small volume of 10 mM Tris-HCl, 0.1
mM EDTA pH 8.0.

The DNA was stored at 4°c or frozen at -20°c.

Isolation of Plasmid pBR322.

One liter of L broth containing 5 µg/

ml tetracycline was inoculated with 10 ml of a 50 ml overnight preculture of

~·

coli strain RRl.

The organism was grown with shaking in a

35°c incubator (17) to a reading of 100 on a Klett-Summerson model 800-3
colorimeter (No. 66 red filter).

The bacteria were pelleted at 8,000 rpm

for 5 min in a Sorvall GSA rotor.

The supernatant was discarded, and

the pellets were resuspended in ice-cold TE buffer (0.05 M Tris-HCl,
0.05 M EDTA pH 8.0) and repelleted a second time.

The pellets were then

resuspended in 0.05 M Tris-HCl, 0.05 M EDTA pH 8.0 containing 15% suerase and 1 mg/ml lysozyme.

This suspension was incubated at room tern-

perature for 10 min followed by the addition of 0.1% Triton X-100 in
0.05 M Tris-HCl, 0.05 M EDTA pH 8.0.

The lysate suspension was incu-

bated at 37°C for 30 min followed by short incubations at 55°c until
lysis appeared complete.

The lysates were centrifuged at 19,000 rpm for

0

1 h at 4 C in a Sorvall SS-34 rotor.

The non-viscous supernatant was

removed and added to CsCl containing 0.1 mg/ml ethidium bromide for a
final density of 1.59 g/cm 3 •

The sample was centrifuged at 38,000 rpm

for 38 h in a Beckman VTi 50 rotor.
The lower u-v fluorescent band in the gradient was collected.

The

ethidium bromide was removed from the collected material by repeated extraction with isopropanol saturated with 20X SSC (lX SSC is 0.15 M NaCl,
0.015 M trisodium citrate).

The plasmid DNA sample was dialyzed over-

night against 10 mM Tris-HCl, 0.1 mM EDTA pH 8.0.
cipitated with ethanol as outlined above.

The dialysate was pre-

A 10 µl aliquot of the plasmid
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.sample was subjected to agarose gel electrophoresis directly.

Another

aliquot of the sample was digested with restriction enzymes HindIII and
HinfI, and the fragments were analyzed by agarose gel electrophoresis.
Cloning Procedure.

Approximately 1 µg of CMV DNA and 0.1 µg of

the vector pBR322 were digested separately with BamHI.

The digests were

ethanol precipitated and resuspended in ligase buffer (60 mM Tris-HCl
pH 8.0, 33 mM NaCl, 10 mM MgC1 ) containing ATP (0.5 mM) and DTT (5 mM).
2
The ligation reaction mixture contained the precipitated digests of insert (CMV) DNA and vector (pBR322) DNA at a concentration ratio of 10:1
and 1 unit of T ligase.
4

A control reaction mixture contained only di-

gested vector DNA with the same reagents.

Both ligation and control

mixtures were incubated overnight at 14°c.

Following incubation the

reaction mixtures were again precipitated with ethanol and resuspended
in 60 µl of 0.1 M Tris-HCl pH 7.2.

Aliquots of the concentrated mix-

tures were subjected to agarose gel electrophoresis for analysis.
The streptomycin-resistant
hsdM , recB,

~'

!· coli strain SF8 (genotype: hsdR ,

lop-11 (ligase overproducer supE44), gal-96, leuB6,

thi-1, thr; a gift from Dr. Masajasur Nomura, University of Wisconsin)
was grown in an overnight preculture in 5 ml of L broth.

A 0.2 ml sam-

ple of this preculture was added to 20 ml of L broth and grown to a
Klett reading of 100.

Transformation of the ligation reaction mixture,

the control mixture and a standard pBR322 untreated control was performed according to the method outlined in Davis et al. (17).

The bac-

teria were sedimented by centrifugation at 5,000 rpm in a Sorvall SS-34
rotor for 5 min at
cold 50 mM CaC1

z0 c.

The pelleted cells were resuspended in 10 ml
0

2

and incubated for 5-60 min at 0 C.

The centrifugation

28
and resuspension steps were repeated in a 1 ml volume of CaC1 .
2

The bac-

teria were then added in a 2:1 (v/v) ratio to the ligation mixture, the
control mixture and the untreated pBR322 control and allowed to sit for
0

10 min at o c.
0

10 min at 2S c.

Each sample was incubated for 2 min at 37°c followed by
Ten volumes of L broth were added to each sample and

they were again incubated at 37°C for 20 min.

Dilutions of the cells

from each sample were then plated out on nutrient agar plates containing
ampicillin (100 µg/ml).

Colonies which appeared on the plates from the

ligation mixture transformation were numbered and picked to nutrient
agar plates containing either ampicillin (100 µg/ml) or tetracycline
(10 µg/ml).

Colonies which were resistant to arnpicillin but sensitive

to tetracycline were selected for further plasmid analysis.
Rapid Technique for Plasmid Analysis.

Recombinants from the clon-

ing procedure were analyzed by the method of Holmes and Quigley (SS).
The organisms were grown overnight in l.S ml of L broth.

Half of the

cell suspension was transferred to a l.S ml microfuge tube and pelleted
for 3 min at 4°c in a Fisher model 23S microfuge.

The supernatant fluid

was removed and the pellets were resuspended in 100 µl STET buffer (SO mM
Tris-HCl pH 8.0, SO mM EDTA, 8% sucrose, S% Triton X-100).

Eight micro-

liters of a 10 mg/ml solution of lysozyme was added and the tubes were
placed in boiling water for 40 sec.

The tubes were recentrifuged for

0

0

10 min at 4 C and the supernatant was precipitated with ethanol at -18 C
for S min.

After another S min centrifugation the precipitates were re-

suspended in water at room temperature.

Aliquots of these samples were

then subjected directly to agarose gel electrophoresis.

For restriction

enzyme digestion analysis the samples were precipitated a second time
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with ethanol and treated with RNase A for 30 min at 37°C.
Agarose Gel Electrophoresis.

Electrophoresis of undigested viral

or plasmid DNA was performed on 0.7% horizontal agarose gels in a buffer
(pH 8.0) containing 89 mM Trizma base, 2.5 mM EDTA, 89 mM boric acid with
a constant current of 50 mAmp for 3-4 h.

Bacteriophage lambda DNA

standards ranging from 0.125 µg to 1.0 µg were placed on the same gels
for quantitation.
For analysis of restriction enzyme digests the samples were electrophoresed at a constant current of 17-19 mAmp for 18-20 h.

HindIII

digests of lambda DNA were run as molecular weight standards on the same
gels.

Following electrophoresis all gels were stained with ethidium

bromide (0.5 µg/ml), placed on a u-v transilluminator and photographed
with Polaroid type 55 film.
Large-Scale Isolation of Recombinant Plasmid DNA.

Ten milliters

of a 50 ml overnight preculture was used to inoculate 1 L of A.B. minimal medium containing no antibiotics.
shaking at 35°c.

The organism was grown with

When a Klett reading of 90-100 was reached, chloram-

phenicol (250 µg/ml) was added to the culture medium for plasmid amplification.

Incubation was continued for 14-16 h at which time the cells

were harvested.

The plasmid DNA was isolated as outlined above for

pBR322 (17).
Restriction Endonuclease Digestion.

Single digests of CMV_or plas-

mid DNA were performed with the restriction enzymes BamHI, EcoRI, HindIII,
BglII or PstI.

The buffer used for all digests contained SO rnM Tris-HCl

pH 7.5, 10 rnM MgC1

2

and 50 mM NaCl and 1 mM DTT.

The reaction mixtures

were incubated at 37°c for 60 min except for those containing Pstl, which
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were incubated at 30°C.

The reactions were stopped by heating at 65°c

for 5 min.
For double digests the DNA was first digested with BamHI for 60
nu·n at 37°C.

Th e sa 1 t concentrat i on was a d.Juste d wh ere necessary; t h e

second enzyme was added, and incubation was continued for another 20 min
0

0

at 37 C except for the PstI digests, which were incubated at 30 C.

Re-

0

actions were again stopped by heating the samples at 65 C for 5 min.

In

later experiments both enzymes were added together at the beginning of
the double digestion and allowed to react for a total of 60 min in the
buffer described above.
Southern Blotting.

Identification of selected cloned fragments

was carried out by standard hybridization techniques (80,114).

CMV DNA

was digested with BamHI, EcoRI or HindTII and subjected to agarose gel
electrophoresis as outlined above, and the gel was stained with ethidium
bromide for 1 h.

The DNA was nicked by exposing the gel for 4 min to

u-v light using a transilluminator.

The gel was destained with distilled

H 0 for 30 min, washed with gentle agitation two times for 15 min each
2
with 0.5 M NaOH/1.5 M NaCl and neutralized by washing two times for 20
min each with 0.5 M Tris-RC! pH 7.5/1.5 M NaCl.

The DNA was then trans-

ferred from the gel to a nitrocellulose filter overnight using a BRL
blotting apparatus with !OX SSPE buffer (1.8 M NaCl, 100 mM NaH Po .H 0,
2 4 2
10 mM EDTA).

At the end of the transfer the gel was restained with ethi-

dium bromide and photographed to determine how much DNA remained.

The

filter was baked in a vacuum oven at 80°c for 2 h and then placed in a
heat-seal bag.
Nick Translation.

Nick translation (106) of the probe DNA was per-
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formed using a nick translation kit (Amersham).

The probe reaction mix-

ture contained 1-2 µg probe DNA, 20 µl buffer solution, 1-2 µl (a-

32

P)-

dCTP (10-20 µCi) and 10 µl of enzyme solution in a volume of 100 µl.
0

The reaction was allowed to proceed at 15 C for 90 min at which time it
was stopped by the addition of 100 µl of 0.02 M EDTA containing 0.2% SDS.
The probe mixture was loaded on a 10 ml Sephadex G-50 column equilibrated
in 50 mM Tris-HCl, 10 mM EDTA.
with a Geiger counter.

Progress down the column was monitored

Approximately 1.5 ml.of buffer containing the

probe was collected after the predetermined void volume.

The probe was

denatured by heating to 95°c for 10 min then quick-cooled on ice.
Hybridization.

Prehybridization of nitrocellulose filters was

carried out in heat-seal bags containing a solution of 5X SSPE, 0.3% SDS
and 100 µg/ml denatured calf thymus DNA.

Approximately 30 ml of the pre-

hybridization fluid was added for a 20 x 20 cm filter, and the sealed
bag was incubated at 65°C for at least 1 h.
The GeneScreen Plus membranes (New England Nuclear) were prehybridized according to the manufacturer's protocol in a solution containing 0.2% PVP, 0.2% ficoll 400, 0.2% BSA, 0.05 M Tris-HCl pH 7.5, 1 M NaCl,
0.1% sodium pyrophosphate, 1% SDS, 10% dextran sulfate and 100 µg/ml calf
thymus DNA.

The prehybridization was carried out in a heat-seal bag at

"
cons t an t ag1"t a t•ion.
65 °c for 6 h ~ith
Half of the probe sample was added to the nitrocellulose filters
in fresh hybridization fluid in the heat-seal bag.
carried out at 65°c overnight.

Hybridization was

The filter was removed and washed with

gentle agitation four times for 30 min each at 45°c in 100-150 ml 2X SSPE
containing 0.2% SDS.

The filter was dried for 2 h at room temperature
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and then placed between two pieces of Kodak X-Omat AR X-ray film in a
cassette with Cronex Lightning Plus intensifier screens {Dupont).

The

0

cassette was held in a -70 C freezer for 19-20 h.
For the GeneScreen Plus membrane hybridizations the denatured
probe was added to the prehybridization fluid along with 100 µg/ml denatured calf thymus DNA.

The membranes were incubated with agitation

for 36-48 h.
The washing procedure for the GeneScreen Plus membranes was as
follows: twice with 100 ml 2X SSC at room temperature for 5 min each;
twice with 200 ml 2X SSC/1% SDS at 65°C for 30 min each; twice with
100 ml O.lX SSC at room temperature for 30 min each.

Membranes were air-

dried and placed in an X-ray cassette as previously described.
Preparation of Filters for Direct Cell or Virus Hybridization.
MRC-5 cells grown in 16 x 125 nun tubes or 25 cm
with CMV AD169 or clinical CMV isolates.

2

flasks were infected

The inoculum consisted of dif-

ferent dilutions of the virus, and infection was allowed to proceed for
various periods of time.

The cells were harvested by trypsinization,

washed in IX EBSS, pelleted at 1500 rpm for 15 min in a Beckman Model
TJ-6 centrifuge and resuspended in 100-200 µl of EBSS.
lutions of the cell suspensions were also made.

Appropriate di-

Nitrocellulose or Gene-

Screen Plus membranes were spotted with 5 µl of the cell suspensions or
dilutions and allowed to air dry.

The membranes were processed by

placing them on top of strips of Whatman 3MM chromatography paper· soaked
in the following solutions as described by Brandsma and Miller (7): 0.5 M
NaOH for 7 min; 0.6 M NaCl/0.5 M Tris-HCl pH 6.8 twice for 1 min each;
1.5 M NaCl/0.5 M Tris-HCl pH 7.5 for 5 min.

The membranes were air-dried
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for 20 min, floated on 95% ethanol and again air-dried for 5 min.

They

were then washed twice in chloroform, air-dried for 15 min and washed
with 0.3 M NaCl.

The nitrocellulose filters were baked in a vacuum oven

0

at 80 C for 3 h; the GeneScreen Plus membranes

r~quired

no baking.

Extracellular samples of the different virus strains or purified
viral DNA were also spotted directly on GeneScreen Plus membranes.
.2

place more than 20 µl o f the sample in a 2 cm

To

area it was necessary to

spot 10 µl aliquots and allow the filter to dry.

Additional 10 µl ali-

q uots could then be spotted over the same area as long as complete
drying occurred between applications.

These membranes were prepared for

hybridization in the same manner as those spotted with cells.
In later experiments a Minifold (Schleicher & Schuell, Keene, NH)
dot blot filtration apparatus was used to prepare GeneScreen Plus membranes for direct hybridization of the probe to infected cells or cellfree virus DNA.
the wells.

The membrane was prepared by suctioning lX SSC through

Sample volumes up to 0.5 ml could then be placed in the

appropriate wells and filtered under slight vacuum.
Processing of Clinical Specimens.

Ten milliliter samples of urine

specimens submitted for CMV culture were collected and stored at -70°c
in a 15 ml centrifuge tube for simultaneous analysis.
thawed at 55°c.

The samples were

The urines were centrifuged at 3,000 rpm for 5 min in

a Beckman TJ-6 centrifuge, and the supernatants were transferred to
15 ml Corex tubes (Corning).

The samples were centrifuged at 14,000 rpm

for 90 min at 4°C in a Sorvall SS34 rotor.

The supernatant was dis-

carded; the pellet was treated with 0.25 ml of 0.3 M NaCl/0.5 M NaOH;
the samples were vortexed briefly and allowed to stand for 15 min at
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room temperature.

An equal amount of 1 M sodium acetate was added.

The

entire sample was placed in a well of the Minifold filtration apparatus
and drawn through the GeneScreen Plus membrane with a slow vacuum.

The

membranes were then treated according to the above procedure for spotting of infected cells or cell-free virus.

The hybridization procedure

was also the same as previously described.

In addition to autoradio-

grams of the membrane, scintillation counting was performed on specimen
squares cut from the membrane.
Nick Translation of Biotinylated Probe DNA.

Nick translation of

pNSL225 was carried out according to the Enzo-Biochem protocol for the
nick translation kit.

Tritiated dATP (12 µl) was lyophilized in a 1.5 ml

centrifuge tube to remove the ethanol.

Following lyophilization the kit

reagents were added in order: 5 µl nick translation buffer, 5 µl nucleoside triphosphate solution, 5 µl biotinylated dUTP, 1 µg DNA, 4 µl
DNase I (appropriately diluted), 4 µl DNA polymerase I, water for a
final volume of 50 µl.
bath for 2 h.

The reaction mixture was placed in a 14°C water

To stop the reaction 5 µl of the stop buffer (0.2 M EDTA)

was added.
The biotinylated probe was separated from unincorporated nucleotides on a 3.5 ml Sephadex G-50 column equilibrated with 10 mM Tris-HCl
pH 7.5, 1 mM EDTA.

Five-drop fractions were collected; 2 µl aliquots

of each fraction were counted by liquid scintillation.

Fractions for-

ming the first peak of radioactivity were collected and pooled.
Alternatively the reaction mixture was placed on a spin column.
The spin column was constructed as described in the Enzo-Biochem protocol using a 1 ml tuberculin syringe filled with Sephadex G-50 equili-
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brated with 10 mM Tris HCl, 1 mM EDTA and placed inside a 15 ml conical
centrifuge tube.

The column was packed by low-speed centrifugation

(1500 rpm for 4 min in a Beckman TJ-6 centrifuge).

A 1.5 ml Eppendorf

tube was used to collect the probe material which passed through the
column following low-speed centrifugation under the exact conditions
used to pack the column.
Hybridization and Detection of Biotinylated Probe.

Prehybridiza-

tion of spotted membranes was carried out according to the GeneScreen
Plus manufacturer's protocol as described above.

The hybridization

solution contained: 0.02% PVP, 0.02% ficoll 400, 0.02% BSA, 5X SSC, 50%
formamide, 20 mM Na phosphate buffer pH 7.0, 10% dextran sulfate, 0.1%
SDS, 1 mg/ml freshly boiled calf thymus DNA, 200-500 ng/ml freshly
boiled probe DNA.

The membranes with the hybridization fluid were placed
0

.

in a heat-seal bag and incubated with shaking at 42 C for 24-48 h.

At

the end of this period the membranes were washed as follows: twice for
15 min each in 2X SSC/0.1% SDS at room temperature; twice for 15 min
0

each in the same solution at 65 C; once in 2X SSC alone for 15 min at
room temperature.
The washed membranes were blocked in a dish containing a solution
of 2% BSA and 0.1% Triton X-100 in lOX PBS for 1 h at 37°c.

The horse-

radish peroxidase complex (Detek I-hrp) was diluted in buffer as provided by the detection kit, added to the membranes in a heat-seal bag
and incubated for 30 min at 37°c.

The membranes were then removed from

the bag and washed as follows: 3 times for 5 min each in 0.5 M NaCl,
10 mM phosphate buffer pH 6.5.

0.1% BSA, Tween 20 (0.5 ml/l) at room

temperature; 2 times with 2X SSC, 0.1% BSA, Tween 20 (0.5 ml/l).
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The enzyme substrate was prepared by adding 10 ml of 10 mM TrisHCl pH 7.5 to 2.5 mg of diaminobenzidine tetrahydrochloride (DAB).
Cobalt chloride (100 µl of a 1% solution) was added to the DAB, which
was then placed on ice for 10 min in the dark.

Finally 7.5 µl of 30%

H o was added, and the solution was applied to the membrane in a heat2 2
seal bag.

The bag was placed in the dark for 10 min for full color

development.

After this time the membrane was washed with 2X SSC and

examined for probe hybridization.

RESULTS
Growth Characteristics, Titer and Plaque Purification of CMV.
Samples of CMV AD169 could be passaged in culture from the extracellular tissue culture fluid once the CPE had reached approximately 50%.
Higher extracellular titer, however, occurred 2-4 days after 100% CPE
was reached (57,124).

Attempts to passage cell-free fluid with less

than 50% CPE were routinely unsuccessful, although passage of infected
cells to new monolayers was possible whenever there was detectable CPE.
Three clinical isolates (LU-1, LU-2, LU-3) were originally highly
cell-associated.

In infected monolayers the CPE remained less than 25%

even after weeks of culture.

Monolayers were repeatedly passaged when

CPE had been visible for 1-2 weeks.

After approximately 4-5 passages of

infected monolayers over a period of several months, the virus became
less cell-associated.

CPE progressed to 100% of the monolayers, and

passage of the tissue culture fluid alone was sufficient to infect new
monolayers.

Continued passage of the supernatant fluid of these strains

resulted in a further increase in the titer of the extracellular fluid
(Table 1).
For all strains of CMV it was necessary to passage the virus at a
low MOI (less than 1) to achieve a high extracellular virus titer.

The

ntnnber of defective particles increases when the MOI is greater than
one, which means the pfu to particle ratio decreases (16,112, Table 1).
The titers were determined by the plaque assay method of Wentworth
and French (140) except that 24-well plates were used instead of 60 mm
37
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TABLE 1
Titers of CMV strains after passage.

Isolate
Number

Original
Titer (p'fu/ml)
6

AD-169

lxl0

AD-169

6
7
lxlO -lxlO

LU-1

2xl0

LU-2

lx10

LU-3

lxlo

5
4
5

Titer after
Passage (pfu/ml)
2xl0

2

6
7
lxlO -lxlO
4.5xl0
lxl0
l.5xl0

7
6
6

MOI
>l
0.01-0.001
0.01-0.001
0.01-0.001
0.01-0.001
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dishes.

This change made it possible to inoculate a larger number of

replicate cultures with fewer cells for each assay.

One other modifica-

tion involved plating the cells well below confluency and allowing them
to grow for 24-48 h to slight subconfluency.

The cells were then much

more adherent and less easily disrupted by the virus inoculation and
subsequent agarose overlay.

For the isolates of AD169 and the clinical

strains LU-1, LU-2, LU-3, the highest extracellular titer observed was
4.5 x 10

7

(Table 1).

Depending on the passage and growth conditions the

titers usually ranged between 1 x 10
the optimal titer of 5 x 10

8

6

and 1 x 10 7 , which is lower than

reported for the CMV Towne strain (75).

The use of roller bottles, however, increased the titer approximately
ten-fold (Table 2).
The plaque assays were also used for plaque purification.

By

selecting wells in which there were fewer than 5 plaques it was possible
to pick isolated plaques for passage to 25 cm

2

flasks.

It was necessary,

however, to wait until there was some clearing of the cells in·an infected focus to assure the presence of extracellular virus in the overlay medium.
of the focus.

This usually required 5-7 days from the initial appearance
Since the plaques were selected from the highest dilu-

tions, the time from inoculation to the appearance of plaques in these
wells was generally 12-14 days.

With additional time to clearing of the

plaque the total time required for plaque selection was about 3 weeks.
. 2
The plaque-purified inoculum was then passaged to HFS cells in 25 cm
flasks at an MOI between 0.01 and 0.001 to propagate the virus for further plaque purification or for freezing for stock samples.

Aliquots of

the final plaque-purified samples were examined by electron microscopy
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TABLE 2
Effect of culture vessel on titer of CMV AD169.

Experiment
Number

Culture Vessel

Titer of
Supernatant
(pfu/ml)

1

2
24 flasks (150 cm )

2x10

2

2
24 flasks (150 cm )

lxl0

3

10 roller bottles
(850 cm2)

4x10

7
7
8

Total Virus
Yield (pfu)
l.7xlo
8.4xl0
5.0xlo

10
9

11
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for morphological confirmation, that the virus was CMV.
To obtain a stock of AD169 for large-scale isolation of DNA the
original sample was plaque-purified three times.
7
had a titer of 2.5 x 10 •

The final stock virus

To maintain the stock a 1 x 10-

the plaque-purified virus was passaged in 25 cm

2

flasks.

6

dilution of

When the MOI

was appropriately low, CPE did not appear for at least 7 days after inoculation.

A very few discrete foci 'of infection appeared at that time,

and these progressed to 100% CPE by 12-14 days.

The

extracel~ular

fluid

was ready for harvest 3-4 days later.
Large-Scale Growth and Purification of Virions.

Several modifi-

cations were made in this procedure because there was difficulty in
obtaining sufficient quantity of virus for DNA extraction.

In the ear-

liest experiments the virus was propagated in 24 tissue culture flasks
2
(150 cm ), which yielded about 850 ml of culture fluid and titers of
approximately 1 x 10

7

pfu/ml.

roller bottles were used.

To increase the total virus yield 850 cm

2

The total surf ace area of the inoculated

monolayers was more than twice the total area of the 150 cm

2

flasks, and

at the same time the total tissue culture fluid volume required to maintain the roller bottle cultures was only 1.5 times greater than the
volume for the flasks (1200 ml versus 850 ml).
In all purification procedures attempted the supernatant fluid
was first cleared of cell debris by low-speed centrifugation.

In the

earliest experiments the virus was pelleted by ultracentrifugation
through a sorbitol cushion (124,126), which allows the best preservation
of infectivity.

A modification which was introduced later was the use

of 5% PEG 6000 to precipitate the virus from the supernatant fluid fol-
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lowed by low-speed centrifugation to pellet the virus (34,52).

There

were visible viral pellets obtained with both of these methods, but the
total yield was still insufficient for adequate DNA extraction (Table 3).
Further purification steps in both of the above procedures involved the use of a discontinuous CsCl gradient (124) or a discontinuous
sorbitol gradient (130).

Both of these manipulations appeared also to

decrease the final virion yield, although visible bands appeared at the
appropriate interfaces (Table 3).
To follow the virus through these purification steps the original
cultures were labelled with

3
H-thymidine.

In addition the infectivity

of the material obtained after each step was tested.

In most of the ex-

periments there was significant radioactivity and infectivity associated
with the collected samples.
The problems encountered in the earlier attempts to purify the
virus seemed to involve either insufficient initial viral titer or loss
of virions during purification.

To simplify the procedure the clarified

supernatant fluid from 10 roller bottles was directly pelleted at 23,430
x g without a sorbitol cushion or PEG precipitation (75).

This modifi-

cation led to the successful collection of a sufficient quantity of
virus for DNA extraction.
Extraction of DNA.

The procedure published by Stinski et al.

(124,126) was followed for the first attempts to extract viral DNA.

The

virions were lysed and digested with Sarkosyl, SDS and proteinase K.
lysate was added to CsCl with ethidium bromide (50 µg/ml) at a density

3
of 1.56 g/cm •

At equilibrium the ethidium bromide was present as a

red band at the interface of the CsCl solution and the mineral oil.

The

Table 3.

Experiment
Number

Stunmary

Culture
Vessel

of DNA isolation procedures.

Sorbitol PEG
Cushion ppt

Gradient
Purification
of Virions

Ly sis
Procedure

Gradient
Purification
of DNA

Results

1

24 flasks
(150 cm2)

+

-

20-70% Sorbitol
CsCl(l. 26g/ml)

Sarkosyl/SDS
Proteinase K

CsCl/EtBr
(1. 56g/ cm3)

No DNA detected

2

24 flasks
(150 cm2)

+

-

20- 70% Sorbi tol Sarkosyl/SDS
Discontinuous
Proteinase K
CsCl(l.2/l.4g/ml)

CsCl/EtBr
( 1. 56 g/ cm3 )

No DNA detected

3

24 flasks
(150 cm2)

+

-

Discontinuous
Sorbitol
(75/48/20%)

SDS
Pronase

Cs Cl
( 1. 72g/ cm3)

Radioactive peak
Faint band of DNA
on agarose gel

4

24 flasks
(150 cm2)

-

+

Discontinuous
Sorbitol
(75/48/20%)

SDS
Pronase

Cs Cl
( 1. 72g/ cm3 )

Radioactive peak
No band of DNA on
agarose gel

5

24 flasks
(150 cm2)

-

+

Discontinuous
Sorbitol
(75/48/20%)

SDS
Pronase

Cs Cl
(1. 72g/ cm3)

Radioactive peak
Faint band of DNA
on agarose gel

6 &7

10 roller
bottles
(850 cm2)

-

-

Sarkosyl
SDS
Pronase

-

-

Total yield 2.5 µg
DNA at a concentraof "' 12.5 µg/ml

~

w
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The band was apparent under normal light and was brightly fluorescent
under u-v light.

There was no fluorescent band of DNA at the appropriate

density and no peak of radioactivity.

Similar results occurred repeat-

edly with this procedure.
A second lysis procedure was followed in which the virions were
treated with SDS, RNase A and pronase (130).

The lysate was added to

3
CsCl without ethidium bromide at a density of 1.716 g/cm •

This is the

density of CMV DNA, which is significantly different from that of cell-

3
ular DNA (1.69 g/cm ), thus, there should have been no difficulty in
separating viral DNA from any cellular DNA contamination.

In fact only

a single peak of radioactivity was present in any of the CsCl gradients
performed on viral lysates, and this peak was always very close to a density of 1.716 g/ml (Figure 3).

In two experiments the material recovered

from the CsCl produced a faint band following agarose gel electrophoresis.
A rough estimation of the concentration of the DNA based on lambda DNA
standards was less than 1 µg/ml.

Attempts to concentrate the DNA by

ethanol precipitation were, however, unsuccessful.

In spite of the fact

that there appeared to be a small quantity of DNA extracted in each experiment, there was not enough to perform restriction endonuclease digestion analysis or to clone the fragments.
The method of DNA extraction which was finally successful was a
modification of the procedure of LaFernina and Hayward (75).

The pel-

leted virus, which was resuspended in buffer, was first subjected to
RNase digestion before lysis of the virions.

This differed from the pub-

lished procedure, which called for the addition of RNase at a later stage
in the extraction process.

It seemed reasonable to remove contaminating
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Figure 3.

Fractions from CsCl gradient containing CMV AD169 DNA.
The DNA sample was added to CsCl at a density of 1.716
g/cm

3

and centrifuged in a Beckman type 50 rotor at

35,000 rpm for 48 h.

Fractions (35 drops each) were

collected from the bottom, and the radioactivity of
20 µl aliquots of each fraction was determined.
3
H-labelled DNA
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RNA before release of the DNA, since viral lysis should not produce any
additional RNA.
After the RNase treatment the virion suspension was lysed directly
with Sarkosyl and SDS, which resulted in almost complete clearing of. the
fluid.

The subsequent addition of pronase removed any residual tur-

bidity.

Another modification in the procedure was the incubation time

in the presence of pronase.

Two hours rather than overnight seemed to be

sufficient for the digestion.

Following phenol and chloroform extrac-

tions the lysate was dialyzed directly without purification in a CsCl
gradient.

Since no gradient was involved, radioactive labelling of the

DNA was not necessary, and there was less chance of losing DNA with
additional manipulations.

The dialysate was concentrated by ethanol pre-

cipitation, and the resulting DNA sample contained approximately 2.5 µg
'

at a concentration of 12.5 µg/ml (Figure 4).
Isolation of Plasmid pBR322.
cloning vector for CMV DNA fragments.
coli strain RRl.

The plasmid pBR322 was chosen as the
The source of the plasmid was ]..

Following extraction from the bacteria the plasmid DNA

was centrifuged in CsCl (1.65 g/ml) with ethidium bromide at 38,000 rpm
in a VTi 50 rotor for 38 h.

At equilibrium there were two bands about

two-thirds of the way down the gradient.

The upper portion of the gra-

dient including the upper band containing chromosomal DNA was removed
from above.

The lower band of plasmid DNA was collected in a total vol-

ume of 2.4 ml.

The ethidium bromide was extracted with isopropanol sat-

urated with 20X SSC.

After overnight dialysis, 5 and 10 µl samples were

loaded on an agarose gel along with a known isolate of pBR322 (a gift
of Dr. S.K. Farrand).

Bands which were assumed to represent linear, open
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Figure 4.

CMV AD169 DNA after ethanol precipitation.

Electro-

phoresis was performed on a 0.7% agarose gel at a constant current of 40 mAmp for 3 h.

After electrophor-

esis the gel was stained with ethidium bromide.
Lanes:

(1) CMV AD169 DNA
(2) A DNA 0.125 µg
(3) A DNA 0.25

µg

(4) A DNA 0.50

µg

(5) A DNA 1.0

µg

1

2

3 4

5
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circle and supercoiled plasmid DNA were present in both pBR322 preparations.

The corresponding forms of these two plasmid isolates migrated

to the same points in the gel indicating that the newly isolated plasmid
was probably pBR322.
For further proof of the identity of the plasmid, restriction
endonuclease analysis was performed.

If all the bands on the gel rep-

resented forms of pBR322, then digestion with a restriction enzyme which
had only one cleavage site in this plasmid should produce homogeneous
linear fragments to form a single band after gel electrophoresis.
Double enzyme digests would provide even more information.

The plasmid

and the known isolate of pBR322 were, therefore, treated with the restriction enzymes HindIII, HinfI or both.

HindIII digestion produced

a single band of linear DNA, since there is only a single HindIII site
in pBR322 (80).

This band migrated with the 4.34 kb fragment of a

HindIII digest of A DNA, which would be expected since the size of
pBR322 is 4.3 kb.

HinfI digestion produced ·several fragments the larg-

est of which (A fragment) is 1.1 kb in size.
a single HindIII site.

This HinfI A fragment has

As expected double digestion of the plasmid with

HinfI and HindIII, produced two smaller bands of the appropriate size
from the original A fragment.
The restriction enzyme patterns observed confirmed that the sample plasmid was pBR322.

The bands matched those of the standard pBR322

preparation when digested with the same restriction enzymes.

In addi-

tion the double digest produced the expected change in the HinfI A fragment.
Cloning of CMV AD169 DNA Fragments in pBR322.

BamHI was selected
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for the cloning procedure, because insertion at the BamHI site in the
vector pBR322 consistently inactivates the tetracycline resistance
carried by the plasmid (80).

The disadvantage of BamHI is that it

cleaves the CMV genome into more fragments than other restriction enzymes such as HindIII or XbaI (49,141).

E. coli strain SF8 was selected

for the subsequent transformation.
The first attempt at cloning produced only twelve transformants
of which two were recombinants demonstrating tetracycline sensitivity.
One contained a double insert of two small fragments of around 2 kb each,
and the second contained a single insert co-migrating with the smaller
insert of the other recombinant.

The ligation control plates showed no

transformants, but the supercoiled pBR322 control DNA produced a large
number of transformants.

These results suggested that components of the

ligation reaction mixtures were inhibiting transformation.

During the

cloning procedure neither the CMV and vector DNA digests nor the ligation mixture were ethanol precipitated.

For the second cloning attempt

ethanol precipitation was performed after both of these steps.

Of 482

ampicillin resistant colonies 67 were shown to be tetracycline sensitive
indicative of recombinant inserts.

They have been repeatedly passed on

nutrient agar containing 100 µg/ml ampicillin.

The sensitivity to tetra-

cycline has been retained indicating that the recombinants are stable.
Analysis of Plasmid Inserts.

All of the 67 recombinants were

analyzed for plasmid content by the method of Holmes and Quigley (55).
On the basis of the migration of the plasmids relative to intact pBR322
the size of the inserts was classified as small, medium or large.

Those

plasmids which migrated the slowest were selected for restriction diges-
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ion with BamHI to determine whether they contained single or multiple inserts.

The plasmids pNSL215 and pNSL225 appeared to have the largest

single inserts and were chosen for
probes.

large~scale

isolation as potential

The reason large fragments were considered desirable was the

greater likelihood that they would contain base sequences homologous to
all strains of CMV.
A second set of recombinants was analyzed for medium-sized inserts which might contain the U fragment present in the long repeat
segments of the CMV genome (45).

This fragment lies completely within

the long inverted repeats and is, therefore, present in 2 molar quantity
in the complete genome digests (Figure 2).

Choosing such a fragment as

a probe would allow two possible points of homology provided there is
not a great deal of variability among CMV strains in this part of the
inverted repeat regions.

Two recombinants, pNSL45 and pNSL186, were

found to have inserts which migrated with the doublet band containing
the T and U fragments.

These also were subjected to large-scale isola-

tion for further identification.
Identification of Inserted Fragments in Selected Recombinant
Plasmids.

The first step in the identification of the fragments carried

by the four selected recombinants (pNSL45, pNSL186, pNSL215, pNSL225)
involved double restriction enzyme digests.

The restriction enzyme map

of CMV AD169 from Greenaway et al. (49) (Figure 2) was used to choose
the appropriate enzymes.
The plasmids pNSL215 and pNSL225 appeared to migrate with the
first band of the BamHI digest of CMV DNA.
migrating fragments A and B (15 kb).

This band contains the co-

There was also the possibility
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that the closely-migrating fragment C (14 kb) could be the insert.

The

enzymes EcoRI and HindIII were selected for double digests with BamHI.
The A fragment has 3 EcoRI sites and 2 HindIII sites; the B fragment has
1 HindIII site and 1 EcoRI site; the C fragment has 2 HindIII sites and
no EcoRI sites.

EcoRI and HindIII cut pBR322 alone very close to the

same site, thus a double digest of either enzyme with BamHI should yield
a larger 4 kb fragment and a smaller 0.3 kb fragment for the pBR322 portion of the recombinant plasmid.
Figure SA shows the results of these digests.

Lane 11 is pBR322

digested with BamHI, which results in a single band of linear DNA.
Lanes 3 and 4 are double digests of pBR322 with BamHI/HindIII and BamHI/
EcoRI respectively.

The major pBR322 fragment (4 kb) is slightly smaller

than the single BamHI digested pBR322 as predicted.

Lanes 7 and 10 are

BamHI digests of each recombinant with the large insert intact.
6 and 9 are BamHI/EcoRI double digests of each recombinant.
cases the insert has been cut.
double digests.

Lanes

In both

Lanes S and 8 are the BamHI/HindIII

The inserts do not appear to have been altered by

HindIII, because the HindIII recognition site is only about 0.3 kb from
the end of the fragment.
To rule out the possibility that the inserts in the recombinant
plasmids could be the D fragment, further double digests with BamHI plus
PstI, BglII and XbaI were performed.
Figure SB.

The digest pattern is shown in

The insert is cut by PstI into three larger fragments plus

2 very small fragments (Lane S).

XbaI cuts the insert only once (Lanes

7 and 9), and BglII produces 1 larger fragment plus 3 small fragments
(Lanes 6 and 8).
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Figure 5.

Double restriction enzyme digests of plasmids carrying
the BamHI B fragment insert.
A.

Lanes:

(1) pBR322 uncut; (2) CMV AD169 BamHI;

(3) pBR322 BamHI/EcoRI double digest; (4) pBR322
BamHI/HindIII double digest; (5) pNSL225 BamHI/
_!iindIII; (6) pNSL225 BamHI/EcoRI; (7) pNSL225 BamHI;
(8) pNSL215 BamHI/HindIII; (9) pNSL215 BamHI/EcoRI;
(10) pNSL215 BamHI; (11) pBR322 BamHI.

B.

Lanes:

(1) pBR322 BamHI; (2) pNSL215 BamHI;

(3) pNSL215 BamHI/EcoRI; (4) pNSL215 BamHI/HindIII;
(5) pNSL215 BamHI/PstI; (6) pNSL215 BamHI/BglII;
(7) pNSL215 BamHI/XbaI; (8) pNSL225 BamHI/BglII;
(9) pNSL225 BamHI/XbaI; (lO)A HindIII.

<(
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It can be concluded, therefore, that the double digests of both
plasmids are

~onsistent

the B fragment.

with the pattern which would be predicted for

Single HindIII or EcoRI digests were performed on

pNSL215 and pNSL225 to determine the orientation.of the inserts (Figure 6).

Both HindIII digests (Lanes 4 and 5) have two fragments approx-

imately 4.3 kb and 15 kb in size.

The EcoRI digests (Lanes 3 and 4)

each show fragments of about 9 kb and 10.3 kb.

The opposite orientation

of the insert in the plasmids would yield HindIII fragments of 0.6 kb
and 18.7 kb, and EcoRI fragments of 5.3 kb and 14 kb.

The orientation

of the inserts is, therefore, the same in these two plasmids.

The re-

striction patterns for both enzymes (HindIII and EcoRI) are consistent
with orientation I depicted in Figure 7.
The double digests for the 2 recombinants suspected of carrying
the U fragment are shown in Figure 8.

The restriction enzymes BamHI

plus PstI, EcoRI and HindIII were used to distinguish the U fragment from
the QRS (6.5 kb), T (5.6 kb) and V (5.4 kb) bands.

The U fragment should

have no HindIII or PstI sites and a single EcoRI site (Figure 2).
fragment has at least 3 PstI sites.
for at least 2 of the 3 enzymes.

The T

Fragments QRS and V all have sites

From Figure 8 it can be seen that both

plasmids carry inserts which are not cut by HindIII (Lanes 9 and 13) or
PstI (Lanes 7 and 11), but which are cut by EcoRI (Lanes 8 and 12).

~-

-~

Again the patterns of the two plasmids appear identical, therefore; both
apparently contain the U fragment.
The second approach to the identification of the inserted fragments in the selected recombinants was to produce radiolabelled probes
by nick translation of the recombinant plasmids and to hybridize them to

57

Figure 6.

Single restriction enzyme digests of pNSL215 and pNSL225
to determine the orientation of the CMV AD169 BamHI
B fragment insert at the BamHI site in pBR322.
Lanes: (1) A. DNA (0.25 µg) digested with HindIII
.(2) pNSL215 EcoRI

(3) pNSL225 EcoRI
(4) pNSL215 HindIII
(5) pNSL225 HindIII

(6)

A.

DNA (0.75 µg) HindIII

1 2

3 4

5

6
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Figure 7.

Restriction enzyme maps of pNSL215 or pNSL225 showing
fragments expected for each possible orientation.

The

CMV AD169 BamHI fragment B insert is at the BamHI site
in pBR322.

The enzyme recognition sites (arrows) are:

BamHI (B), HindIII (H) and EcoRI (E).

Fragment sizes

produced by digestion with either HindIII or EcoRI for
each orientation are given.

ORIENTATION

Hind III

I

EcoRI

ORIENTATION

PNSL215/225

PNSL215/225

Hind III

"2RI
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Figure 8.

Double restriction enzyme digests of plasmids carrying
the BamHI U fragment insert.
Lanes: (1) pNSL186 uncut; (2) pNSL45 uncut; (3) pBR322
BamHI/PstI double digest; (4) pBR322 BamHI/EcoRI;
(5) pBR322 BamHI/HindIII; (6) pBR322 BamHI; (7) pNSL186
BamHI/PstI; (8) pNSL186 BamHI/EcoRI; (9) pNSL186 BamHI/
HindIII; (10) pNSL186 BamHI; (11) pNSL45 BamHI/PstI;
(12) pNSL45 BamHI/EcoRI; (13) pNSL45 BamHI/HindIII;
(14) pNSL45 BamHI; (15) A digested with HindIII
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different enzyme digests of total CMV DNA.

For the two plasmids pNSL215

and pNSL225 the CMV DNA was digested with EcoRI, HindIII and BamHI.
probe was made with pNSL225.

A

The CMV DNA digests show that the probe

binds to a single large BamHI fragment, a large HindIII fragment and 2
large EcoRI fragments (Figure 9).

This is consistent with the pattern

expected for the B fragment of the BamHI digest.
quence

(~

There is a short se-

0.3 kb) at the end of the B fragment which would be expected to

be homologous to the HindIII L fragment (Figure 2).

Hybridization of the

probe to this HindIII fragment is not distinguishable in Figure 9, although the existence of a HindIII recognition site in the insert was demonstrated by the HindIII digests of pNSL215 and pNSL225 (Figure 6).

The

co-migrating BamHI A fragment however, should hybridize to 4 EcoRI fragments and 3 HindIII fragments.

The BamHI C fragment should hybridize to

only 1 EcoRI fragment and 3 HindIII fragments.

The hybridization re-

sults (Figure 9) do not support the possible presence of either of these
inserts.
The hybridization experiment to identify the U fragment is more
difficult to interpret.

Since the U fragment is part of the long repeats,

it can hybridize to joint fragments comprising the junction of the long
and short repeat sequences in other restriction enzyme digests (Figure 1).
These joint fragments (L-S) are present in less than 1 molar concentrations, because there are four possible configurations of the CMV genome.
The T fragment

as well as QRS and V are present only in the unique se-

quences, and therefore, have better defined hybridization patterns.

In

Figure 10 it can be seen that the probe which was made from pNSL45 hybridized to several large HindIII fragments some of which appear to be

64

Figure 9.

Southern hybridization of

32

P-labelled B fragment probe

(pNSL225) with restriction enzyme digests of total CMV
AD169 DNA.

Autoradiogram shown above with corresponding

agarose gel below.
Lanes:

Exposure time 19 hours.

(A) pNSL225 BamHI digest; (B) CMV AD169 DNA

BamHI; (C) CMV AD169 HindIII; (D) CMV AD169 DNA EcoRI.

A

I

c

D
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placed on the same gels for blotting to nitrocellulose.

In Figure 11 it

can be seen that the B fragment probe did not hybridize to any fragments
of the three viruses, while the appropriate hybridization with the CMV
DNA digest clearly occurred.

It should be noted that there was less EBV

DNA than CMV DNA present on the gel.

Similar amounts of CMV AD169 DNA

produce strong hybridization with the probe, but there is 100% homology
between the CMV DNA and the probe.

It could be argued that partial

homology with EBV DNA in such low quantity would not be detected.

A

southern blot using the U fragment probe also showed no hybridization to
the DNA digests of these other herpesviruses.
Hybridization of the Probe with Infected Cells.

The initial ex-

periment was set up in duplicate using both a nitrocellulose filter and
GeneScreen Plus membrane for comparison.

MRC-5 cells in 16 x 125 mm

tubes were inoculated starting 10 days before the expected harvest date.
Two tubes each day were inoculated with a 10purified CMV AD169.

5

dilution of stock plaque-

On the day of harvest the cells were trypsinized

and two ten-fold dilutions were made of the cells from each day of inoculation.

4
The filters were spotted with 5 µl volumes representing 10 ,

3
2
10 , and 10 cells from 10 days down to 2 days postinfection.
tion HSV-1, HSV-2, EBV and CMV DNA were spotted.

In addi-

The filters were

treated according to the procedure of Brandsma and Miller (7).

The nitre-

cellulose filter, however, was baked only 3 h instead of 18 h, and ,the
GeneScreen Plus membrane was not baked at all.
by nick translation of pNSL225.

The probe was produced

Hybridization of both filters was car0

ried out in heat-seal bags at 65 C for 43 h, but the GeneScreen Plus was
constantly agitated in a water bath, while the nitrocellulose was placed
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Figure 11.

Southern hybridization of

32

P-labelled B fragment probe

(pNSL225) with HSV-1, HSV-2, EBV and CMV AD169 total
DNA BamlII digests.

Autoradiogram shown above with cor-

responding agarose gel below.

Exposure time 20 hours.

Lanes: (A) pNSL225 BamlII digest; (B) EBV BamlII;
(C) HSV-2 BamlII; (D) HSV-1 BamlII; (E) CMV AD169 BamlII.
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in an oven and only occasionally flipped and rocked.
In this first attempt to hybridize the CMV probe with infected
cells the GeneScreen Plus membrane produced more encouraging results than
the nitrocellulose.

In both cases there was too much background hybrid-

ization, but there were definite spots for 10
post-infection and for the CMV DNA.
more difficult to interpret.
of hybridization.

4

cells from 10 to 5 days

The nitrocellulose filter was much

The CMV DNA spot was the only definite area

It was decided to use the GeneScreen Plus instead of

nitrocellulose for future experiments, because it gave better results,
was easier to handle and required no baking.

The one disadvantage of

GeneScreen Plus is the 6-hour minimum prehybridization reconnnended by the
manufacturer.
In the next experiment with infected cells the viral inocula were
clinical isolates of CMV.

The B fragment (pNSL225) was used as the probe,

and the hybridization was performed in the same manner as that outlined
for AD169-infected cells.
all CMV isolates tested.

Figure 12 shows that the probe hybridizes to
However, as noted above there is no hybridiza-

tion to uninfected cells nor to HSV-1 and HSV-2 DNA.

From this experi-

ment it can be concluded that the probe can detect more CMV strains than
just the stock strain AD169 from which it was made, and there is no crossreactivity with the 2 strains of HSV which were tested.

This suggests

that this probe may have both sensitivity and specificity for CMV.

The

infected cells showed 50-80% CPE depending on the isolate, therefore, no
quantitative conclusions can be drawn concerning the degree of sensitivity nor can the possibility of cross-hybridization with other strains
of HSV be ruled out.
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Figure 12.

Hybridization of

32

P-labelled B fragment probe (pNSL225)

with cells infected with CMV AD169 or passaged clinical isolates of CMV.

Exposure time 20 hours.

Columns:

(A) CMV AD169; (B) LU-1; (C) LU-2; (D) LU-3.

Rows:

(1) lx10 3 infected MRC-5 cells; (2) lxl0
fected cells; (3) lxl0 5 infected cells.
6

Control:

lxlO

Squares:

(Gl) HSV-1 F DNA 0.1 µg

uninfected MRC-5 cells

(G3) HSV-2 333 DNA 0.1 µg
(Hl) CMV AD169 DNA 0.01 µg
(H4) pNSL225 DNA 0.1 µg
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A more quantitative experiment was performed directly on virus
particles spotted on the membrane (Figure 13).

Dilutions of stock sam-

ples of three clinical isolates and AD169 were placed on the membrane
and processed according to the method of Brandsma and Miller (7).
one set of dilutions for each virus sample 2.75 x 10
were spotted along with the virus.

3

For

uninfected cells

There appeared to be no significant

difference between the virus alone and the virus plus cells for any of
the CMV isolates.

There was no hybridization with uninfected cells alone.

HSV-1 and HSV-2-infected cells were tested along with separate samples of
naked HSV-1 and HSV-2 DNA.

There was no hybridization with the HSV-in-

fected cells and only slight hybridization with 1 µg of HSV DNA.

There

was 50 times as much RSV DNA as control CMV DNA on the membrane, therefore, the background hybridization with the HSV DNA is unlikely to be a
problem in other experiments.
ranged from 1 x 10
LU-1, 4 x 10

4

6

to 2.5 x 10

to 4 x 10

2

The number of pfu which the probe detected
3

for AD169, 1.8 x 10

6

to 4.5 x 10

4

for

4
2
for LU-2, and 6 x 10. to 6 x 10 for LU-3.

The hybridization of LU-3 with the probe appears as strong as that
of AD169 and LU-1.

The titer of this isolate, however, is only slightly

higher than that of LU-2.

A possible explanation of this discrepancy may

be that there is a larger number of defective virus particles in the LU-3
preparation.

This would yield a greater amount of DNA relative to the

number of pfu detected in the plaque assay.
Another experiment was designed to determine how large an inoculum
of virus might be required for detection within 72 h of inoculation of
cells in culture.
2 x 10

7

Ten-fold dilutions of an AD169 stock sample containing

pfu/ml were used to inoculate MR.HF cells in 16 x 125 mm tubes.

11
j
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Figure 13.

Hybridization of 32P-labelled B fragment probe (pNSL22S)

with cell-free virus or virus plus uninfected cells.

Exposure time

23 hours.
Columns: (A) AD169 cell-free virus: lxlO
2.Sxl0

4

pfu (3); 2.Sxl0

3

6

pfu (l); 2.SxlO

pfu (4); 2.Sxl0

3

s

pfu (2);

pfu (S).

(B) AD169 cell-free virus plus lxlo 3 uninfected MRC-S cells
(same number pfu as in column A).
6
(C) LU-1 cell-free virus: l.8xl0 pfu (l); 4.SxlOS pfu (2);
4.SxlO

4 pfu (3).

(D) LU-1 cell-free virus plus lxlO

3

uninfected MRC-S cells

(same number pfu as in column C).
4
4
(E) LU-2 cell-free virus: 4xl0 pfu (l); lxlO pfu (2);
lxlO

3

pfu (3).

( F) LU-2 cell-free virus plus lxlO

3

.

uninfected MRC-S cells

(same number pfu as in column E).
(G) LU-3 cell-free virus: 6xl0
l.SxlO

3

4

pfu (l); l.SxlO

4

pfu (2);

pfu (3).

(H) LU-3 cell-free virus plus lxlO

3

uninfected MRC-S cells

(same number pfu as in column (G).
(I) HSV-1-infected MRC-S cells (l); HSV-1 DNA, 1 µg (2);
HSV-2-infected MRC-S cells (3); HSV-2 DNA, 1 µg (4);
pNSL22S DNA 0.2 µg (S).
(Z) Dilutions of CMV AD169 DNA: 10 ng (l); 1 ng (2);
100 pg (3); 10 pg (4).

Hybridization on separate mem-

brarie under same conditions as samples in columns A-I.
Control (ES): lxl0 3 uninfected MRC-S cells.

CMV AD169 DNA (GS): 20 ng
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Figure 13.

Hybridization of

32

P-labelled B fragment probe (pNSL22S)

with cell-free virus or virus plus uninfected cells.

Exposure time

23 hours.
Colwnns: (A) AD169 cell-free virus: lxlO
2.Sxl0

4

pfu (3); 2.Sxlo

3

6

pfu (l); 2.SxlO

pfu (4); 2.Sxl0

3

s

pfu (2);

pfu (S).

(B) AD169 cell-free virus plus lxlo 3 uninfected MRC-S cells
(same number pfu as in column A).
(C) LU-1 cell-free virus: l.8xl0
4.SxlO

4

6 pfu (l); 4.SxlO s pfu (2);

pfu (3).

(D) LU-1 cell-free virus plus lxlO

3

uninfected MRC-S cells

(same number pfu as in column C).
(E) LU-2 cell-free virus: 4xl0
lxlO

3

4 pfu (l); lxlO 4 pfu (2);

pfu (3).

(F) LU-2 cell-free virus plus lxlO

3

uninfected MRC-S cells

(same number pfu as in column E).
(G) LU-3 cell-free virus: 6xl0
l.SxlO

3

4 pfu (l); l.SxlO 4 pfu (2);

pfu (3).

(H) LU-3 cell-free virus plus lxlO

3

uninfected MRC-S cells

(same nwnber pfu as in column (G).
(I) HSV-1-infected MRC-S cells (l); HSV-1 DNA, 1 µg (2);
HSV-2-infected MRC-S cells (3); HSV-2 DNA, 1 µg (4);
pNSL22S DNA 0.2 µg (S).
(Z) Dilutions of CMV AD169 DNA: 10 ng (l); 1 ng (2);
100 pg (3); 10 pg (4).

Hybridization on separate mem-

brarie under same conditions as samples in columns A-I.
Control (ES): lxl0

3

uninfected MRC-S cells.

CMV AD169 DNA (GS): 20 ng
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TABLE 4
Correlation of culture results with probe hybridization
to clinical urine specimens
Clinical
Specimen
Number

Culture

Autoradiogram

Radioactivity of
Spotted Membrane ( cpm)

1

61

2

70

3

83

4

58

5

+

+

448

6

51

7

75

8

76

9

58

10

95

11

62

12

80

13

+

70

14

67

15

33

16

Not Done

17

II

18

II

19

"

20

"

21

II
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Table 4.

(Cont'd)

Clinical
Specimen
Number

Culture

Autoradiogram

Radioactivity of
Spotted Membrane (cpm)
Not Done

22

"

23

Background (unspotted membrane sample)

80

Unlabelled pNSL225 DNA
(1 µg in 0.5 ml lX SCC)

+

133, 280

+

29,051

Unlabelled pNSL225 DNA
(1 µg spotted directly)
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passage of the original inoculated monolayer, was also negative with the
probe.

The second culture-positive specimen was from a patient with sus-

pected AIDS.

The original culture was positive within 72 h and both the

autoradiogram and scintillation counting

fro~

the prepared urine specimen

showed strong binding of the probe (Figure 14).

The autoradiogram in

Figure 14 also contains two of the culture-negative clinical specimens
which fail to bind the probe.

There are two faint areas of hybridiza-

tion which correspond to cells from monolayers infected with HSV-1 and
HSV-2.

This was the only experiment in which there was background hybrid-

ization with these two viruses.

The RSV samples contained cells whereas

the clinical specimens were cell-free.

It may be that the processing of

the membrane during this experiment was inadequate to remove cellular
material which might nonspecifically bind the probe.

In addition, a dif-

ferent cell type (MRHF) was inoculated with the viruses.
MRC-5 cells had been used.

Previously

The possibility of probe binding to MR.HF

cells should be investigated for any future experiments which require
virus-infected cells.
The procedure for processing the clinical specimens was a modification of that of Chou and Merigan (13).

The salt concentration of

the NaOH/NaCl solution used to disrupt the pelleted virions was lowered
from 2M to 0.3M such that the final concentration of the specimen to be
filtered would be equal to that of lX SSC (0.15 M NaCl).

This change was

instituted on the advice of the GeneScreen Plus manufacturer (New England
Nuclear) to achieve optimal binding of DNA to the membrane.

To check for

adequate binding of DNA to the membrane 1 µg of unlabelled probe DNA was
added to 0.5 ml lX SSC and filtered with the Minifold apparatus.

Another
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Figure 14.

Direct hybridization of B fragment probe to patient
urine specimens.

The large spots in column A represent

1 µg of unlabelled pNSL225 DNA either spotted directly
(row 2) or placed in 0.5 ml lX SSC and filtered onto
the membrane (row 1).

Faint spots in row 3 of columns

B and C are HSV-1 and HSV-2-infected ·MR.HF cells.

The

large spot in column C row 4 is the sample from the
suspected AIDS patient.

Two other culture-negative

clinical samples were spotted in row 4 columns A and B
but did not bind the probe.

Exposure time 23 hours.

A
1

2

3

4

B

· C
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1 µg was spotted directly on the membrane.

Both DNA samples hybridized

to the probe equally (Figure 14).
Biotin-Labelled Probe.

The biotin-labelled probe was first hy-

bridized to a duplicate membrane corresponding to Figure 12.
stock AD169 and the three clinical isolates, 10
visualized.

For the AD169 and LU-1 samples, 10

duced an easily visible color reaction.
LU-2 and LU-3 were very much fainter.
as was the control containing 10

6

5
4

For both

infected cells could be
infected cells also pro-

The corresponding dilutions of
All other dilutions were negative

uninfected cells.

The CMV and pNSL225

DNA controls were positive, and HSV-1 and HSV-2 DNA spots were negative.
These results suggested a 10-100 fold lower degree of sensitivity for
the biotin probe over the corresponding radiolabelled probe.
The next membrane to which the biotin probe was hybridized was a
duplicate of that in Figure 13.

The probe failed to detect any of the

virus or virus plus cells samples.

Probe and CMV DNA were of the same

color intensity as in the previous experiment.

There was no hybridiza-

tion to HSV-1 or HSV-2 DNA nor to the control cells.

The total lack of

color reaction for any of the virus samples was unexpected, since all
samples were readily detected with the radiolabelled probe.

Both mem-

branes were inoculated at the same time and prehybridized using the GeneScreen protocol.

The same biotin probe sample from the previous experi-

ment was reused for this membrane, which is in agreement with the_manufacturer's recommendations.

The positive controls seemed to be valid.

From this experiment it would appear that the biotin probe is even more
than 100-fold less sensitive than the radiolabelled probe.

It should be

noted, however, that the amount of CMV DNA present in heavily infected
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cells far exceeds the amount of DNA which would be released from cellfree virus stocks.

Thus the amount of DNA on the membrane in the pre-

vious experiment is much greater than that in this experiment.

The dif-

ficulty in interpretation arises from the direct comparison of the
biotin and radiolabelled probes in this experiment.
The biotin probe was next hybridized to the same dilutions of
naked CMV DNA seen in Figure 13.

A visible color reaction was present

for the 100 pg but not for the 10 pg dilution.

This represents more

than a 10-fold difference in sensitivity, since it would appear from
the autoradiogram that less than 10 pg of DNA might be detected, and the
100 pg spot on the biotin probe membrane was very faint.
The biotin probe was hybridized to the first 11 of the 23 clinical urine specimens.

Variable color reactions occurred in the inocu-

lated areas with no correlation to the culture or autoradiographic results.

The specimen from the suspected AIDS patient showed the same

amount of color development as several culture-negative specimens.

Some

of the other culture-negative specimens had background color produced
by substances present in the urine sediment.
Only 20% of each prepared clinical urine specimen was actually
spotted on a membrane for hybridization to the biotin probes.

Sixty

percent of the specimen was filtered with the Minifold onto a membrane for hybridization to the

32

P-labelled probe.

In Figure 14 it

can be seen that the culture-positive specimen from the suspected
AIDS patient was positive by autoradiography, and that other culture
negative specimens were negative by this technique as well.
parison of the hybridization of the biotin and

Com-

32
P-labelled probes
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with culture results of these clinical specimens suggests that the bio32

tin-labelled probe binds non-specifically, while the

P-labelled probe

hybridization correlates with the culture results.
Another experiment was performed to try to quantitate the biotin
probe sensitivity with stock virus dilutions.

Samples of AD169, LU-1,

LU-2 and LU-3 stock cell-free virus were placed in the Minifold filtration apparatus and applied to a GeneScreen Plus membrane.
sponding pfu for each dilution are listed in Table 5.
that the probe can detect 1 x 10

5

pfu.

The corre-

It would appear

This can be compared to Fig-

ure 13 where the radiolabelled probe detected 1 x 10

3

pfu of LU-2.

To

make sure that the membrane would bind DNA in solution during the filtration process, 1 µl of pNSL225 DNA was diluted with 0.5 ml lX SSC and
placed in a Minifold well.

Another 1 µl of the pNSL225 DNA was spotted

directly onto the membrane.

Both samples appeared equally clearly on

the membrane after hybridization.

This experiment again suggests at

least a 100-fold difference in sensitivity between the biotin and

32

P-

labelled probes.
No firm conclusion concerning the relative sensitivity of the
biotin probe should be made, however, since there were some technical
variations and difficulties in following the manufacturer's protocol.
The protocol was revised by Enzo-Biochem for the amount of probe DNA required for hybridization.

There were also changes made by the manu-

facturer in the hybridization method, which may account for some of the
variability of the results.

For example the final membrane washing

with 2X SSC after color development was added to the original protocol.
This step reduces the background color.

In addition two different
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TABLE 5
Quantitation of biotin probe sensitivity
Virus pfu
AD169

6
1 x 10

++

1 x 10 5

+

1 x 10
1 x 10
LU-1

Color DeveloEment

4
3

1. 8 x 10

1.8 x 10

6
5

++
+

1.8 x 10 4
1. 8 x 10
LU-2

1.5 x 10
1.5 x 10
1.5 x 10
1.5 x 10

LU-3

3
5

-+

4
3
2

1 x 10 5

+

1 x 10 4
1 x 10 3
1 x 10
Control

2

pNSL225 DNA (1 µg)

++++
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methods were used for retrieving the probe following nick translation.
The original probe samples were placed on a 3.5 ml Sephadex G-50 column
and fractions were collected.

Since

3
H-labelled ATP was added to the

nick translation reaction in addition to cold ATP, the incorporated
label could be used to select the fractions containing the probe.
Another method was the use of a 1 ml Sephadex G-50 spin column
(Enzo-Biochem protocol).

Theoretically the 50 µl nick translation vol-

ume should be recovered in approximately equal volume after centrifugation in an Eppendorf tube at the tip of the Sephadex column.

The actual

volume which was collected in 4 different nick translation reactions
varied from 200-500 µl.

To check that the

3
H-labelled probe was sep-

arated from unincorporated nucleotides, one of the probe samples was
placed on a 3.5 ml column and fractions were collected as before.

There

was only one peak of radioactivity, which occurred right behind the void
volume; therefore, the probe had been separated but was present in too
large a volume.

The samples were each ethanol precipitated; recounting

indicated that the probe was concentrated.

It may be, however, that

more probe was lost during the purification steps of the spin column
technique than during purification on the 3.5 ml Sephadex column.

A

loss of biotinylated probe would have reduced the apparent sensitivity
of the hybridizations in the last experiment described above.

DISCUSSION
Tissue culture has been the standard method for virus isolation
and identification in the laboratory.

The method is both specific and

sensitive in that a single plaque-forming unit of virus can be amplified
from the original inoculum to produce visible CPE.

However, replication

of many viruses is very slow in tissue culture; the method is expensive,
and not all viruses can be easily propagated in cell types coIIUilonly
used for virus screening.
Recently the need for more rapid diagnostic tests for viral infections has increased with the introduction of antiviral chemotherapy.
Many of the currently approved drugs have very narrow spectra of antiviral activity (53), which makes identification of the etiologic agent
important for treatment of each individual viral disease.

In addition

monitoring of the progress of treatment requires rapid laboratory results (13,81,105,118) •. Rapid identification of viral disease can also
curtail the need for extensive diagnostic testing and aid in the epidemiologic control of virus dissemination (105).
The use of nucleic acid probes shows promise as a technique for
rapid viral detection and identification.

Richman et al. (105) were

able to detect 1 pg of purified HSV DNA or 10
with several HSV probes.

4 pfu of cell-free virus

Herpes simplex type specificity was achieved

with probes carrying fragments from the junction region of the genome
(105) or by increasing the stringency of the hybridization conditions
(122).

Similar probes developed for the detection of EBV (3,7) were
89
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able to detect 2-5 pg of DNA.

Hybridization methods for identification

of adenovirus (134) and human papilloma virus (16) have been recently
reported.

Probes for RNA viruses have also been developed.

Type-spe-

cific probes for rotaviruses were shown to hybridize to 8 pg of homologous double-stranded RNA (33).
licase gene of coxsackievirus B3

A copy DNA probe containing the repcould detect other enteroviruses in

tissue culture inoculated with stool specimens (63).

Hybridization in

culture occurred with coxsackieviruses A and B, echovirus, and poliovirus.

The sensitivity, however, was not sufficient to detect these

viruses directly in the original specimen.
The slow growth of CMV in routine laboratory tissue culture has
prompted a search for faster methods for detecting this virus, and DNADNA hybridization has been one line of investigation (13,81,118).

The

goal of this project has been the development of a DNA probe for rapid
detection and identification of CMV.

Several steps were required in

the development process: 1) isolation of CMV DNA from strain AD169; 2)
cloning of BamHI restriction endonuclease fragments of the viral DNA;
3) selection and identification of an appropriate cloned fragment for a
probe, and 4) determination of the sensitivity and specificity of the
radiolabelled and biotin-labelled probe for CMV.
Cytomegalovirus AD169 is a well-characterized laboratory strain
for which there is a restriction map available (49).

This

strai~

was

used as a source of viral DNA, because the virions are released extracellularly.

Typical wild-type CMV strains remain highly cell-associated.

The extracellular virions provide a source of viral DNA which is free of
cellular DNA.

Cellular debris can be removed by low-speed centrifuga-
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tion before the virus particles are pelleted from the supernatant fluid.
The method of DNA isolation which finally allowed the production of
enough DNA for cloning did not require further purification of the pelleted virus (76).

The virions were lysed directly after resuspension

in a small amount of buffer.

The lysate was extracted twice with or-

ganic solvents and then dialyzed.

No gradient was required at any

point during the procedure, and DNA suitable for restriction enzyme
analysis was obtained.

The BamHI restriction endonuclease digestion

pattern (Figure 9) of the isolated CMV DNA matches that published by
Huang et al. (60) for strain AD169.

Furthermore the lack of a fluor-

escent background suggests that the CMV DNA is chemically pure and not
contaminated with other DNA species.
The plasmid vector pBR322 was chosen for its ready availability
and well-characterized restriction map (18,82).

BamHI was chosen as

the enzyme to produce DNA fragments for cloning, because inactivation
of tetracycline resistance by insertion at the BamHI site in pBR322 provides a consistent screening marker for recombinant plasmids.

HindIII

has been used by others (75) to produce cloned CMV fragments.

The ad-

vantage of this enzyme is that it cuts the DNA into fewer fragments than
does BamHI, and the largest -fragments of the .HindIII digest are considerably larger than the largest BamHI fragments.

The disadvantage of

HindIII is that insertion at the HindIII site in pBR322 does not
sistently inactivate tetracycline resistance.

~on

Cytomegalovirus AD169

DNA fragments have been cloned into the EcoRI site in pACYC184 (129).
EcoRI also has fewer restriction sites in the CMV genome, but there is
no selection marker for insertion at the EcoRI site in pBR322.

The
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largest EcoRI fragments are not much larger than the largest BamHI fragments; therefore, there seemed to be no advantage to using the EcoRI/
pACYC184 system.

Insertion at the Pstl site inactivates the ampicillin

resistance marker of pBR322, but two of the largest restriction fragments produced from CMV AD169 DNA are found in the junction region of
the genome.

These fragments are present in only 0.25 M quantity in the

total CMV DNA digest, which means that only one-fourth of the viral
genomes contain the intact fragment sequence.

This enzyme also pro-

duces significantly smaller fragments than does BamHI.

The enzyme which

produces the largest and fewest restriction fragments in CMV AD169' DNA
is Xbal, but there is no restriction site for this enzyme in pBR322.
Thus, considering all of the commonly used enzymes and vectors, BamHI
with pBR322 seemed to be the most convenient combination to use for
cloning.
A cloned fragment to be used as a probe should contain DNA sequences which are connnon to all HCMV strains and which are present in
all

con~igurations

of the genome.

recombinant plasmids of interest.

There were, therefore, two types of
First, a plasmid with a large single

insert preferably the A or B fragment of the BamHI digest was sought
for its long unique sequence.

Second, the U fragment was considered

desirable for its 2 molar concentration in the total CMV AD169 genome.
Two plasmids (pNSL215 and pNSL225) were selected for further study, because they had large single inserts.

Both plasmids turned out to carry

the B fragment in the same orientation (Figure 7).

This identification

was established by both restriction endonuclease digestion patterns of
each plasmid insert and hybridization of the radiolabelled recombinant
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plasmid with restriction endonuclease digests of total CMV AD169 DNA
(Figures 5,6 and 9).
Two other cloned plasmids {pNSL45 and pNSL186) were chosen for
analysis, because their single inserts migrated with the band of the
CMV BamllI digest which contained the U fragment.

Both plasmid inserts

were subsequently confirmed to be the U fragment.

Again restriction

endonuclease digestion patterns of the inserts and hybridization of the
32
P-labelled plasmid with total CMV digests were the methods used to
establish the identity of the cloned fragments (Figures 8 and 10).
Based on recent reports of variability among CMV strains in the
repeat regions of the genome (75,143) and sequences in the repeats,
which were at least partially homologous to cellular DNA sequences (85),
it was decided that the U fragment in the
a probe.

I~

might not be desirable for

The B fragment is found in the UL segment of the genome in a

region that has not yet been reported to be either variable among CMV
strains or homologous to cellular DNA (15,86,94,119).

This fragment

was, therefore, chosen for all subsequent experiments.
It was obvious from the fragment identification experiments, that
the probe containing the B fragment hybridized to CMV strain AD169 DNA
(Figure 9).

This probe was then tested for its ability to hybridize

with DNA from laboratory strains of HSV-1 (strain F), HSV-2 (strain 333)
and EBV (strain B95-8).

The Southern blots showed no cross-react_ivity

of the probe with any segment of these DNA digests (Figure 11),

al~

though, as previously mentioned, there was only about half as much EBV
DNA as CMV DNA present on the filter.

The only other human herpesvirus

which would be of clinical significance is VZV, but unfortunately no
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DNA from that virus was available for testing.

We can conclude from

these experiments that the CMV B fragment probe shows no detectable hybridization with DNA from these strains of HSV-1, HSV-2 and EBV.

It

still remains possible that the DNA from other isolates of these viruses
or from VZV could cross-react with the probe.

However, other reports

(59,94) suggest it is unlikely that llllder the conditions of hybridization used in these experiments, there would be

su~ficient

homology be-

tween the genomes of these viruses and CMV to alter the specificity of
the probe.

In converse experiments, Richman et al. (105) demonstrated

that RSV probes did not hybridize with CMV- or VZV-infected cells.
Since the probe was a construct containing a unique sequence DNA
fragment of CMV strain AD169, it was necessary to demonstrate that it
could hybridize with other strains of CMV.

The three clinical isolates

which were initially tested were obtained from specimens submitted to
the clinical virology laboratory for culture.

Repeated passage of in-

fected monolayers eventually led to the production of 100% CPE with
release of infectious virus into the culture supernatant fluid.

The

probe could then be used to detect both cell-free virus and virus-infected cells (Figures 12 and 13).

The probe hybridized very strongly to

these isolates under either cell-free or infected-cell conditions.
These results do not prove conclusively that the probe can detect all
human strains of CMV, but there appears to be sufficient homology reported among HCMV strains (58,142) to suggest that the probe should be
able to detect all clinical isolates.
Quantitative experiments were designed to determine the amount
of CMV DNA and the number of plaque-forming llllits of intact virus re-
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quired to produce a visible reaction by autoradiography.

The 10 pg sam-

ple of CMV AD169 DNA could easily be seen on an autoradiogram after 20
hours of exposure (Figure 13).
of CMV.

This represents about 4 x 10

4 genomes

The degree of sensitivity in the picogram range is in agree-

ment with that reported by Chou and Merigan (13).

No purified DNA from

strains of CMV other than AD169 was available for testing; therefore,
the sensitivity of the probe could differ among CMV strains, if there
were any variability of the sequences homologous to the AD169 BamHI
fragment.

The evidence from the experiment using dilutions of cell-

free virus from the clinical strains LU-1, LU-2 and LU-3 (Figure 13),
however, suggests that the B fragment probe is probably nearly as sensitive for strains other than AD169.

The intensity of hybridization of

the probe with each of these clinical strains correlates with the number of pfu spotted on the membrane.

For example the three dilutions of

6
5
4
strain LU-1 represent 1.8 x 10 , 4.5 x 10 and 4.5 x 10 pfu respectively, and the intensity of the spots on the autoradiogram decreases
with each dilution.
is 1 x 10

3

The lowest number of pfu detected with the probe

pfu represented by the highest dilution of strain LU-2.

This

degree of sensitivity is similar to that reported by others (13).
The amount of CMV DNA which is actually present for each dilution
in Figure 13 is difficult to determine, since the ratio of pfu to viral
particles is very low for CMV and may well vary from one preparation of
virus to another.

The many noninfectious particles may contribute DNA

which will increase the intensity of probe hybridization.

A correla-

tion between pfu and probe sensitivity may, therefore, be misleading
without electron microscopy to show the number of viral particles con-
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taining DNA.

In addition there may be many virions containing defec-

tive DNA, which might include a deletion of some or all of the B fragment sequences.

The evidence presented here, however, generally in-

dicates that the radiolabelled probe is likely to detect at least the
majority of HCMV strains with a reasonably high degree of sensitivity.
In comparison with the

32
P-labelled probe the sensitivity of the

biotinylated probe was found to be at least 100-fold lower when the
nick translation was performed according to the protocol published by
Enzo-Biochem.

Dilutions of CMV AD169 DNA could barely be visualized at

the 100 pg level whereas the radiolabelled probe was easily able to
produce a dark spot on the autoradiogram with 10 pg of DNA.

Equivalent

membranes carrying dilutions of stock virus sainples (Figure 13 and
Table 5) also showed the much lower sensitivity of the biotin probe as
compared to the

32

P-labelled probe.

The next step was to hybridize the radiolabelled probe to actual
clinical specimens to see if the probe could directly detect CMV before
inoculation of tissue culture.

Samples from urines sent to the clinical

laboratory for CMV culture were processed for autoradiography.

A mul-

tiple filtration apparatus (Schleicher and Schuell Minifold) was used
so that all of the pelleted sample could be spotted on the membrane.
The results of the hybridizations with the clinical specimens show that
virus present in urine can be pelleted and detected directly with the
radiolabelled probe (Figure 14), but quantitative levels of detection
have not been determined.

One specimen, which was positive by both cul-

ture and autoradiography was from a suspected AIDS patient, who appeared
to be excreting a high titer of virus.

This was indicated by the fact
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that CPE was present within 72 hours after culture inoculation.

The

one specimen which was culture-positive but negative by autoradiography
and scintillation counting had a very low viral titer.

The initial cul-

ture was negative and a blind passage became positive with very few infectious foci after several weeks of incubation.

All other urine spec-

imens from this patient have been culture-negative for CMV.

The re-

maining clinical specimens (21 out of 23) tested were culture-negative
and showed no hybridization with the probe.
With only two known culture-positive clinical specimens available
the probe has not been adequately tested for direct detection of CMV
in clinical samples.

The data so far only indicate that the probe is

capable of detecting clinical strains of CMV when the virus is present
in quantities sufficient to produce CPE in the initial culture.
Other investigators have successfully used different _CMV probes
for direct detection of the virus in clinical specimens.

Chou and
32

Merigan (13) used the cloned CMV AD169 EcoRI 0 fragment as a

P-la-

belled probe for hybridization to urine specimens and were able to detect virus at a titer of 10

3

or higher in the original sample.

reported no false-positive results.
32

They

Spector et al. (118) hybridized

P-labelled probes carrying the CMV AD169 EcoRI B and D fragments to

huffy coat specimens from bone-marrow transplant patients.

They re-

ported that the DNA-hybridization technique was more sensitive than
tissue culture for detecting CMV infection in these patients.

Marlowe

et al. (81) could demonstrate the presence of CMV in 19 of 20 culturepositive urines as well as three lung biopsy specimens.
belled probe contained cloned fragments of CMV Towne DNA.

Their

32
P-la-
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The use of

32

P for detection of probe hybridization can provide

both sensitivity and rapid results.

Low levels of hybridization can be

visualized by holding autoradiograms for longer periods of time.

Sein-

tillation spectrometry can be used in place of autoradiography to decrease the time required for testing (13).
with the use of

32

The disadvantages associated

P are the short half-life (14 days) and the high

radiation energy hazard of the isotope.
By contrast the main advantages of the biotinylated probe are
the lack of radioactivity and the stability of the probe.

According

to the manufacturer the biotin label is stable for at least a year.

The

Enzo-Biochem nick translation procedure, however, also calls for the incorporation of a small amount of

3
H-labelled ATP as well as cold ATP.

The radioactivity is used as a tracer to facilitate the recovery of the
probe from the unincorporated nucleotides on a Sephadex G-50 column.
Presumably the radiolabel can be eliminated, if either a spin column or
ethanol precipitation method is used for probe recovery.

The Enzo-

Biochem protocol unfortunately does not address the problem of the undesirability of the tritium label.
In addition to lower sensitivity non-specific binding in the
presence of cells or clinical material made the biotinylated probe unsuitable for direct detection of the virus.

Technical difficulties,

however, may be responsible for the unsatisfactory results with this
reagent.
that the

The conclusion drawn from the experiments for this project is
32

P-labelled probe is at the moment much better than the bio-

tinylated probe for detection of CMV.
There are recent reports, however, which suggest that modifica-
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tions in the biotin-labelling procedure can increase the sensitivity of
these probes.

Leary et al. (78) used alkaline phosphatase instead of

hrp for visualization of probe hybridization.
reaction 3.1 pg of DNA could be detected.

In an homologous plasmid

Richman et al. (105) used

this modification and were able to detect 1 pg of HSV DNA, a level of
sensitivity which is equivalent to that of

32

P-labelled probes.

The

biotinylated probe for EBV constructed by Sixbey et al. (112) ·was detected with fluoro&:ein-isothiocyanate- labelled avidin and was found to
be more sensitive than a comparable probe labelled with
Directions for Future Research.
that the CMV BamHI B fragment probe will

32

P.

The evidence so far suggests
dete~t

the majority of HCMV

strains, but further testing will be required to demonstrate that all
isolates from clinical specimens will hybridize to the probe.

For ex-

ample, there is one strain of CMV, strain Colburn, which was originally
isolated from a patient, but which has been shown to be more closely related to simian strains of CMV than HCMV (61,67).

It is also known

that simian strains can be propagated in human cell culture (61,132),
although there are no reports describing human infections with these
viruses.

The B fragment probe from CMV AD169 needs to be tested. against

strain Colburn and other simian strains in the event that in the future
such strains of CMV are found to produce human disease.
The clinical usefulness of the probe has not yet been demonstrated~

Titering of specimens needs to be performed at the time of

initial inoculation to determine the number of pfu originally present.
The sensitivity of the probe for direct detection of CMV in patient
specimens can then be correlated quantitatively with the culture results.
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An additional clinical application of the probe would be the·
identification of CMV in laboratory tissue culture where the titer of
the original specimen was too low to detect directly.

Presently iden-

tification of CMV is based on the rate of appearance of typical CPE and
the types of cells in which the virus will grow.
of identification are often inconclusive (124).

Immunological methods
In situ hybridization

with either the radiolabelled or biotinylated probe could be performed
at specific times after inoculation of replicate tissue culture monolayers.

If this technique were sufficiently sensitive, a positive re-

action could identify infection with CMV before the appearance of CPE.
Positive results would, therefore, be available earlier, and these cultures would require no further laboratory work.
The most clinically significant aspect of nucleic acid hybridization techniques for detection of viruses is the potential for obtaining rapid laboratory results.

The method used for the development

of the probe during this project allows detection and identification of
CMV in 48 h (7).

Chou and Merigan (13) referred to the same hybridiza-

tion protocol but claimed to have results in 24 h.

This means the

period of hybridization would have to be reduced to less than 24 h.
Other reports (81,118), however, support the claim that reliable results can be obtained in 24 h.
Biotin-labelled probes can shorten the time even more, because a
high concentration of probe can be used for hybridization without
raising the level of non-specific binding (78).

Richman et al. (105)

reported that their procedure for RSV could be performed in 5 h.

Future

experiments to demonstrate the clinical application of the CMV probe

Wl
developed for this project should address the question of the rapidity
with which the probe can detect and identify the virus.

Forty-eight

hours for detection of CMV as performed during this project is in most
cases faster than tissue culture, and the specificity of the probe provides more certain identification of CMV than the appearance of the CPE.
The prospect of shortening the time required for complete identification
of this virus adds to the potential clinical usefulness of the probe.
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